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Abstract 
 
C.G. Dodgen 
 
MSc thesis, Department of Biotechnology, Faculty of Natural Sciences, University of the 
Western Cape 
 
The rapidly expanding field of nanotechnology has been the focus of many biologists 
with regard to drug delivery. The ability of nanoparticles to enter cellular compartments 
makes it possible to explore specific treatment strategies for life-threatening diseases 
such as AIDS. Since HIV primarily infects CD4+ cells, we aim to use CD4 as a 
selectable marker to deliver pro-apoptotic nano-devices to HIV infected cells. The 
objective is to selectively induce cell death or apoptosis in CD4+ HIV infected cells. 
Apoptosis is activated through a number of biochemical pathways. The apoptosis 
promoting protease, caspase-3 is central to the induction of apoptosis. Caspase-3 is 
produced as an inactive zymogen and is activated by other proteases through proteolytic 
cleavage. We take advantage of the fact that HIV-infected cells produce HIV-1 protease, 
which is responsible for the production of infectious virions through proteolytic cleavage 
of the HIV proteins, Gag and Pol. Our strategy was to generate a mutant form of the 
caspase-3 protease that is only cleavable by HIV-1 protease.  
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Gold nanoparticles were used to selectively deliver mutant caspase-3 to CD4
+
 cells that 
mimic HIV infection through the use of a CD4-targeting peptide that specifically 
recognizes CD4
+ 
cells.  
Gold nanoparticles were synthesised and functionalised with nitriloacetic acid (NTA). 
Dose response cell culture experiments indicate that NTA-functionalised gold 
nanoparticles did not induce apoptosis or cytotoxicity on their own. NTA-functionalised 
particles were conjugated to a histidine-tagged CD4-targeting peptide, as well as 
histidine-tagged mutant caspase-3. Upon treatment of mammalian cells representing 
HIV-infection, NTA-CD4-targeting peptide-mutant caspase-3 gold nanoparticles showed 
a decline in cell viability at all concentrations tested. Apoptosis was not detected at high 
levels in treated cells after 24 hours, but based on the data, it is likely that early apoptosis 
occurred shortly after treatment, thus not allowing the detection of apoptosis at the 24 
hour timepoint.  
Our results suggest that gold nanoparticles could serve as an effective drug delivery tool 
due to their size and chemical properties. Moreover, mutant caspase-3 targeted to cells 
expressing HIV-1 protease and CD4 seemed to exhibit changes in cellular morphology, 
reminiscent of a process termed autophagy. Additional experimental data would confirm 
the nature of this process, and determine whether this process occurs as a protective 
mechanism until the cellular environment resumes back to normal, or if the changes 
eventually result in death of these cells. This data serves as the basis for further 
investigation of functionalised gold nanoparticles for the eradication of diseased cells.  
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1. The Human Immunodeficiency Virus Type I (HIV-1) 
 
The Human Immunodeficiency Virus, more commonly referred to as HIV, is the cause of 
HIV infection. HIV infection places the infected individual at risk for the occurrence of 
opportunistic infections, resulting in Acquired Immunodeficiency Syndrome (AIDS) (Broder, 
2010). This disease is known to be life-threatening and the cause of millions of deaths across 
the globe every year (Girard et al, 2011). It is not known where exactly HIV originated from, 
but the very first cases of HIV were reported to the National Institute of Health (NIH) in the 
USA in 1981 (Gallo and Montagnier, 2003). During the late 1970s, it was thought that 
epidemic diseases, caused by either bacteria or viruses, no longer threatened developed 
nations (Gallo and Montagnier, 2003). It was during this period that HIV/AIDS started to 
make its appearance. In the early 1980s, AIDS was already identified as a disease, the cause 
of which was unknown at the time. A range of possible causes was investigated, including 
fungi and exposure to chemical agents (Gallo and Montagnier, 2003). In the year 1983, 
research scientists at the Pasteur Institute in France discovered a retrovirus, made clear by the 
presence of the enzyme reverse transcriptase. This virus was recovered from a man with 
persistent generalised lymphadenopathy (PGL), a condition that was suspected to be 
associated with AIDS (Levy, 2006). The virus was found to be similar to the Human T-cell 
Leukemia Virus (HTLV), in that it characteristically depleted CD4 T-cells. However, the 
symptoms of the unknown virus were found to be different from those associated with 
HTLV.  
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This, together with the elimination of the idea that a microorganism (other than a virus) could 
be responsible for the disease, led researchers to start the search for a virus similar to HTLV. 
In 1984, researchers at the Pasteur Institute in France, as well as those in Bethesda, Maryland 
(United States of America) isolated a viral strain that infected all growing T-cell lines. Upon 
the discovery of HIV in 1984, a link was made between HIV and AIDS. The reason for this 
was that HIV was repeatedly found in the bloodstream of AIDS patients and the blood test 
used for this purpose was highly reproducible (Gallo and Montagnier, 2003). It was at this 
time, late in 1984, that HIV was acknowledged in the medical community as being the 
causative agent for the disease known as AIDS and the name HIV was given in 1986 by the 
International Committee on Taxonomy of Viruses (Levy, 2006). According to the United 
Nations Acquired Immunodeficiency Syndrome (UNAIDS) 2010 Report on the Global AIDS 
Epidemic, an estimated 33.3 million people globally are infected with HIV (United Nations 
Acquired Immunodeficiency Syndrome (UNAIDS) Report on the Global AIDS Epidemic, 
2010). 
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1.1 HIV biology 
In order for HIV to effectively infect human cells, it is important that its structure is suited to 
function. The structure of HIV has been determined as a 120 nm spherical particle, comprised 
of various structural and functional proteins. The production of these proteins, essential for 
the survival of the virus, is made possible by a well-organised genome (Girard et al., 2011), 
as shown in Figure 1.1. 
 
 
 
 
 
 
 
 
Figure 1.1. Structure of the HIV-1 genome  
(Adapted from www.yale.edu/bio243/HIV/genome.htm). 
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The genome is comprised of the gag (group-specific antigen), pol (polymerase) and env 
(envelope) genes, which encode the viral nucleocapsid, polymerase and envelope proteins. A 
long terminal repeat (LTR) region flanks these genes, and all of them, together with tat 
(transactivator of transcription) and rev (regulator of viral protein expression), make up the 
genome of the human immunodeficiency virus (Costin, 2007). Free virus, concentrated in the 
blood plasma, begins the process of infection by binding to the immuno-specific CD4 T-
helper cell (Girard et al., 2011). CD4 is a 58 kDA protein that is found on approximately 60% 
of T-lymphocyte cells (Hoffmann et al., 2007). Research has shown that HIV is capable of 
infecting other cells in the body (including monocytes, macrophages and dendritic cells) but 
that the virus has the strongest affinity for CD4. However, it has been established that CD4
+
 
cells promote viral replication, whereas CD4
-
 cells do not (Douek et al., 2002).  
 
1.1.1 Viral entry 
The first step in the infection of these CD4
+
 cells is the binding of the HIV membrane protein 
gp120 to the CD4 cell surface. This protein, which binds to the CD4 receptor, is a structural 
protein synthesised from the env gene (Figure 1). Though it is necessary, the CD4 receptor is 
not the only receptor required for HIV infection and entry into the cell  
(Hernandez et al., 1996; Edo-Matas et al., 2011). CD4 acts as a primary receptor, but co-
receptors, such as CCR5 and CXCR4, are also needed and act as secondary receptors for the 
entry and infection of cells with HIV (Edo-Matas et al., 2011) .  
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Although other co-receptors have been identified, these two chemokines have been 
implicated as being the most active co-receptors during the process of viral entry. 
Experiments done with recombinant human CD4 provided evidence that viral fusion and 
entry was made possible by an Env-mediated reaction, but that a co-receptor was needed to 
facilitate this process (Berger et al., 1999). Although these co-receptors have been positively 
pinpointed as being the active coreceptors during HIV infection, it has also been determined 
that the active coreceptor (either CCR5 or CXCR4), is specific for the HIV-1 variant 
(Hoffmann et al., 2007). Experimental analysis has shown that CXCR4 is the specific 
coreceptor for viral entry in T-cell lines and these variants are therefore called TCL-tropic 
variants (Berger et al., 1999). In the case of primary T cells, both CXCR4 and CCR5 are 
active in viral entry, making these variants of HIV-1 dual-tropic. Finally, in macrophage 
cells, CCR5 has been identified as the coreceptor active in HIV-1 viral entry, and these 
variants are aptly named M-tropic lines (Berger et al., 1999). The fact that these receptors are 
present in specific cells has led to the idea that certain individuals could be resistant to 
specific variants of HIV-1. This was proven when it was found that persons who were 
homozygous for a 32bp deletion in the CCR5 gene, were resistant to infection with that 
particular variant of HIV-1 (Navenot et al., 2001). These important discoveries have also 
made the co-receptors of HIV-1 prime targets for HIV-1 treatment strategies (Tsibris and 
Kuritzkes, 2007). Upon binding to the cellular surface, the gp120 viral membrane protein 
interacts with CD4 on the membrane surface of the target cell. This triggers the activation of, 
amongst others, the CXCR4 and CCR5 cellular receptors, which indirectly allow for the 
engulfment and uptake of the virus into the cell (Tsibris and Kuritzkes, 2007). 
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1.1.2 Reverse transcription and integration 
In order for viral replication to take place, the virus must insert its genome into that of its host 
(Bushman and Craigie, 1991). Upon cellular entry, the HIV-1 virion undergoes an uncoating 
process during which its outer “shell” is removed, exposing the core of the virus. This is then 
followed by a series of events, starting with the binding of tRNA primers (Hoffmann et al., 
2007). Subsequent to tRNA primer binding, the proviral strand of DNA is synthesised, and 
viral RNA is degraded by RNAse H. A template switch from haplogroup R to haplogroup U5 
DNA is followed by full-length polymerisation of the proviral DNA (Hoffmann et al., 2007). 
This polymerisation process is followed by host cellular activation of the viral integrase 
enzyme. Integrase then binds to attachment sites at the end of each viral long terminal repeat 
(LTR). Once the cDNA synthesis from RNA is complete, a cutting process, in which two 
nucleotides are cut from each of the viral LTRs, can occur (Vandegraaff and Engelman, 
2007). The aforementioned process is key during the formation of the pre-integration 
complex (PIC). The viral PIC, as demonstrated in Figure 1.2, is comprised of a number of 
factors, including the viral DNA (transcribed by reverse transcriptase), the matrix protein, 
integrase as well as Vpr. In order for integrase to facilitate DNA-strand transfer, the PIC 
needs to come into close contact with chromatin DNA.  
Integrase is then able to cleave specific viral DNA sequences during 3´ processing 
(Vandegraaff and Engelman, 2007) and the entire PIC is then transported from the host 
membrane to the nucleus, where it is integrated into the host genome (Sherman and Greene, 
2002). 
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Figure 1.2 Pre-integration and nuclear import of HIV. 
(Adapted from Sherman and Greene, 2002). 
 
1.1.3 Post-integration 
Subsequent to viral integration, the synthesised viral DNA undergoes transcription by the 
host organism. This process is facilitated by various elements, but particularly by the nuclear 
transcription factor NF-B, which initiates transcription by binding to the long terminal 
repeat (LTR) of the virus (Trkola, 2004). The regulatory viral proteins, tat and rev, are also 
synthesised at this point. These proteins play a key role in the promotion of transcription of 
viral DNA and the formation of mature viral particles (Hoffmann et al., 2007). Another 
important protein that is synthesised at this point is the HIV-1 protease. The protease is 
needed for the cleavage of the gag-pol polyprotein in order to produce mature, infectious 
viral particles (Simon et al., 2006). Upon completion of transcription, viral transcripts are 
efficiently packaged and the release of mature virus is facilitated by the budding process, an 
almost equal, but opposite process to membrane fusion during HIV entry (Trkola, 2004).  
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1.1.4 HIV-1 protease: structure and function 
HIV-1 protease functions in a critical role to cleave the viral gag-pol polyproteins, as seen in 
Figure 1.3, towards the production of both structural as well as functional viral proteins. The 
importance of the protease has been demonstrated by mutation studies that revealed that in 
the absence of active protease, the virus cannot be formed as an infectious structure (Kohl et 
al., 1988).  
 
 
 
 
 
 
 
Figure 1.3 Cleavage of the Gag-Pol polyprotein by HIV-1 protease (Nijhuis et al., 2007). 
 
The very first crystal structure of HIV-1 protease was obtained by Merck laboratories, which 
was followed by a more detailed structure in 1989 (Brik and Wong, 2003). HIV-1 protease is 
an aspartic acid protease, comprised of two non-covalently bonded identical monomers, 99 
residues long.  
HIV-1 protease has a binding cleft that allows for the cleavage of various viral precursors for 
the production of active protein, as can be seen in Figure 1.4 (Ghosh et al., 2009).  
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Each of the monomers has a glycine-rich loop which partially serves as the substrate-binding 
region. It also houses the essential Asp-25 aspartyl residue, labelled in Figure 1.4, which is 
essential for protease function. Since HIV-1 protease is classified as an aspartic protease, it 
contains the conserved Asp-Thr-Gly domain.  
Mutational analysis, as well as three-dimensional structure of the HIV-1 protease confirms 
that it is similar in both structure and mechanism to the aspartic proteases (Brik and Wong, 
2003). The viral protease is, therefore, similar to other aspartic proteases, including caspases, 
which also play a role in cell death.  
 
 
 
 
 
 
 
Figure 1.4 Crystal structure of HIV-1 protease demonstrating active sites and domains (Adapted from 
Ghosh et al., 2009). 
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1.2 Infection and pathogenesis 
The most common route for infection by HIV-1 is by sexual transmission. It can also enter 
the body via other means, including intravenous drug use, contact with infected blood, 
maternofetal transmission and, in rare cases, during blood transfusion (Hoffmann et al., 
2007). The virus replicates and spreads throughout the body at such a fast pace that it can be 
detected in the blood only 5 days after infection (Kahn and Walker, 1998). This earliest stage 
of HIV infection is known as acute HIV infection. At this stage, approximately 0.1% of the 
body’s total CD4 lymphocytes are infected with HIV (Richman, 2001). During this phase of 
the infection, the virus is replicating at an alarming rate and the individual will present with 
symptoms similar to a viral infection. It is this similarity to common viral infections, such as 
influenza, that makes it difficult to diagnose the patient during this phase (Hoffmann et al., 
2007). Unfortunately, it is also during this phase that correct diagnosis could result in the 
patient receiving the best antiretroviral treatment. This, however, does not occur very often, 
since the symptoms are commonly mistaken for a simple viral infection (Kahn and Walker, 
1998). During this phase, viraemia is at its highest, causing the risk of transmission to be 
highest here. This phase is also concurrent with the rapid decline of CD4
+ 
T cells. The most 
common symptoms associated with acute HIV-1 infection are listed in Table 1. 
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Table 1. Most common symptoms experienced by HIV-1 infected patients (Adapted from Kahn and 
Walker, 1998). 
SYMPTOMS PERCENTAGE PATIENTS 
Fever >80-90 
Fatigue >70-90 
Rash >40-80 
Headache 32-70 
Lymphadenopathy 40-70 
Pharyngitis 50-70 
Myalgia 50-70 
Nausea, vomiting, diarrhea 30-60 
Night sweats 50 
Aseptic meningitis 24 
Oral ulcers 10-20 
Genital ulcers 5-15 
Thrombocytopenia 45 
Leukopenia 40 
Elevated hepatic enzyme 
levels 
21 
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Figure 1.5. Clinical stages of HIV infection (adapted from Pantaleo et al., 1993). 
 
The phase that follows the acute phase is fairly asymptomatic, but disease progression is still 
dramatic, as can be seen in Figure 1.5. The final stage of disease is the development of AIDS. 
It is during this stage that the individual will experience high levels of viraemia, 
complemented by CD4
+
 depletion (Simon et al., 2006).  
These combined features of the disease result in compromised immunity and the patient 
becomes susceptible to opportunistic infections. Since the immune system cannot fight off 
these infections, death is more than likely to ensue (Hoffmann et al., 2007). 
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1.3 Current antiretroviral treatments 
Antiretrovirals have been the topic of much controversy in the pharmaceutical and economic 
world. Their ability to slow down the rate at which cells are infected, and thereby prolong 
life, is countered by a number of setbacks (Adamson and Freed, 2008).  The pill-burden of 
antiretrovirals and various side-effects associated with them have prompted research for 
alternative treatment strategies (Godnick, 2007). Since HIV was discovered, a number of 
antiretroviral agents have been developed and are available for use. These drugs are discussed 
in the next section in further detail. 
 
  1.3.1 Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 
Nucleoside residues can be described as nucleobases attached to either a ribose or 
deoxyribose sugar (Matthews et al., 2000). Analogues of nucleosides, as well as nucleotides, 
are used to inhibit the action of the reverse transcriptase enzyme required for HIV replication 
(Hoffmann et al., 2007). These drug types were the very first anti-HIV drug to be developed 
and were thought to be the solution the world was after (Squires, 2001). These bases are 
rather similar to the naturally occurring nucleosides and nucleotides, with a slight difference 
in, e.g., one base. This difference causes an alteration in the building blocks of DNA, thereby 
interfering with DNA synthesis of HIV (Hoffmann et al., 2007).   
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are still a large component of the 
combination therapy for HIV, and the level of tolerance in patients has proven to be bearable, 
save for the gastrointestinal side-effects and mild headaches (Hoffmann et al., 2007).  
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However, it has been determined that the long-term effects of this type of drug are not so 
minor (de la Rosa et al., 2004). Aside from the well-known mitochondrial toxicity associated 
with these NRTIs (Brinkman et al., 1999), patients also suffer from pancreatitis, lactate 
acidosis and myelotoxicity (Hoffmann et al., 2007). Not only does one have to consider the 
physiological effects of this drug, but the virus has now developed resistance to many of the 
existing nucleoside analogues (Menendez-Arias and Tozser, 2008). 
 
1.3.2 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
 
This group of antiretrovirals are similar to the above-mentioned ones, in that it also targets 
the enzyme reverse transcriptase. Where they do differ, however, is that NNRTIs bind 
specifically to reverse transcriptase to form an enzyme-substrate complex that causes the 
deceleration of reverse transcription action (Hoffmann et al., 2007). Another difference 
between these two inhibitors is that NRTIs require phosphorylation to become active, 
whereas NNRTIs do not (Temesgen et al., 2006). Between the years of 1996 and 1998, three 
NNRTIs were accepted for clinical use. These included efavirenz, nevirapine and delavirdine 
(Hoffmann et al., 2007). Delavirdine, however, is not used very often in the clinical 
environment due to the high dosage required (pill burden) and its low efficacy (Temesgen et 
al., 2006). Amongst the most common effects of delavirdine is the range of central nervous 
system effects. These could range from sleeplessness to mania and occur in as many as 40% 
of patients (Carr and Cooper, 2000).  
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1.3.3 Protease Inhibitors (PIs) 
HIV-1 Protease cleaves the gag-pol polyprotein into its active subunits, generating viral 
protein needed for maturation. If these proteases are inhibited, the virus is unable to produce 
infectious, mature virion (Hoffmann et al., 2007). Protease inhibitors function by inhibiting 
HIV-1 protease, thereby preventing the production of the proteins required for viral 
maturation. These inhibitors are used in combination with other ARVs for the inhibition of 
viral replication (Flexner, 1998). A number of protease inhibitors have been licensed in the 
US and have been made available for use (listed below). Although these inhibitory drugs 
have been used successfully in combination with other ARVs, there remains a range of 
adverse effects associated with PIs (Carr and Cooper, 2000). Aside from the high dose 
required for the drug to function effectively, PIs have also been known to cause 
gastrointestinal disturbances, lipodystrophy, dyslipidemia, sexual dysfunction as well as 
cardiovascular disease (Flexner, 1998). It is for this reason that different approaches are being 
researched for the improvement of HIV drug treatment (Adamson and Freed, 2008). 
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Table 2. Side-effects observed in some individuals after administration of protease inhibitors 
(Adapted from Carr and Cooper, 2000).  
 
 INDINAVIR NELFINAVIR RITONAVIR SAQUINAVIR AMPRENAVIR 
 
 
 
 
 
 
 
 
 
TOXIC 
EFFECT 
Renal calculi Diarrhoea Perioral 
paraesthesiae 
Nausea Hypersensitivity 
Hyperbilirubinaemia Nausea Nausea Diarrhoea Perioral 
paraesthesiae 
Reflux oesophagitis Cytochrome 
P450 interaction 
of drug 
metabolism 
Diarrhoea and 
Flushing 
Cytochrome 
P450 interaction 
of drug 
metabolism 
Cytochrome 
P450 interaction 
of drug 
metabolism 
Retinoid effects Spontaneous 
bleeding in 
haemophiliacs 
Cytochrome 
P450 
interaction of 
drug 
metabolism 
Spontaneous 
bleeding in 
haemophiliacs 
Spontaneous 
bleeding in 
haemophiliacs 
Haemolytic anaemia  Spontaneous 
bleeding in 
haemophiliacs 
  
Cytochrome P450 
interaction of drug 
metabolism 
    
Spontaneous 
bleeding in 
haemophiliacs 
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1.3.4 Other anti-HIV drug developments 
Other than the antiretrovirals that have been developed for reverse transcriptase and protease 
inhibition, research has also focused on a number of entry inhibitors as well as integrase and 
maturation inhibitors (Adamson and Freed, 2008).  Entry inhibitors, as the name suggests, 
inhibits the binding of the viral gp120 to the CD4 receptor, or the co-receptors, CCR5 and 
CXCR4 (Briz et al., 2006), thereby blocking entry of HIV into host cells. Since viral entry 
occurs via three phases, there are also three different types of entry inhibitors. These include 
attachment, co-receptor as well as fusion inhibitors. Of these drugs, a number are currently on 
the market, and include the fusion inhibitor enfuvirtide (Briz et al., 2006), a CCR5 receptor 
inhibitor, maraviroc (Dorr et al., 2005), as well as the integrase inhibitor, raltegravir  
 
1.4 Alternative strategies for HIV-1 eradication 
Due to the increasing occurrence of resistance to antiretrovirals via genetic mutation, 
researchers have been focusing their attention on more effective treatment strategies (Fauci, 
2003). Aside from the increase in the number of antiretroviral developments, there has also 
been a trend toward the eradication of HIV-infected cells by inducing cell death.  
Vocero-Akbani et al demonstrated one such strategy in 1999 when they suggested a Trojan 
horse strategy that specifically targets and kills HIV-infected cells through the initiation of 
apoptosis. HIV-1 protease is necessary for the production of new viral particles (Haseltine, 
1991). This strategy exploits the fact that HIV-1 protease is an aspartic acid protease similar 
to caspases.  
Instead of inhibiting the protease, as with previous strategies, the protease was exploited by 
inserting residues for HIV-1 protease into caspase-3, a cell death-inducing protein (Vocero-
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Akbani et al., 1999). This would allow HIV-infected cells to be killed specifically and 
without the destruction of neighbouring, uninfected cells. This strategy, and others like these, 
could very well be a more permanent answer to the problems we have been faced with for 
more than 20 years (Fauci, 2003).  
 
1.5 Apoptosis 
1.5.1 What is apoptosis? 
Apoptosis can be defined as a process during which cells in the body are programmed to 
undergo a sequence of biochemical events leading to their death. This process is a neat, 
highly controlled one and is often referred to as cellular suicide. This phenomenon was first 
discovered by Kerr et al in 1972, when they referred to this targeted cell death as ‘apoptosis’. 
The term was chosen since it directly translates to ‘falling off’ of leaves from trees in Greek. 
At the time, necrosis, a different type of cell death, was already known (Santini et al., 2000).  
Necrosis was, however, much less controlled when compared to apoptosis. During necrotic 
cell death, cells experience mitochondrial swelling, membrane disintegration as well as 
leaking of cell contents into the surrounding tissues. This results in the activation of the 
inflammatory response, and leads to the eventual death of surrounding, healthy cells. This 
type of cell death, since it is uncontrolled and causes harm to adjacent cells, is more 
commonly referred to as pathological cell death (Kanduc et al., 2002).  
Upon comparison of apoptosis and necrosis, distinct differences have been detected. These 
differences are listed in table 3. 
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Table 3. Necrotic versus Apoptotic Cell Death (Adapted from Zador et al., 2003) 
 
 
 
NECROSIS APOPTOSIS 
Morphological differences 
Membrane integrity lost Membrane blebbing, Membrane integrity 
maintained 
Mitochondrial and organelle swelling Shrinkage and condensation of cytoplasm 
Cell lysis and leakage Cell fragmentation, Vesicle formation 
Biochemical differences 
No energy-dependence Energy-dependent process 
Loss of ion homeostasis Highly controlled enzymatic process 
Randomized DNA digestion Specific, DNA fragmentation 
Physiological differences 
More than one cell affected at a given time One cell targeted and affected 
Pathogical death Death induced by physiological stimuli 
Induction of inflammatory response No inflammatory response 
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During the apoptotic process, cells are individually targeted for elimination. This occurs via a 
number of stages that include cell shrinkage, organelle shrinkage, chromatin condensation 
and the formation of vesicles that are phagocytosed by surrounding macrophages (Matute-
Bello and Martin, 2003). Apoptotic cells are also easily identified by the externalisation of 
phosphatidylserine at their cell surface (Earnshaw et al., 1999).  
Apoptosis does not occur in a large number of cells at a given time, and this type of death is 
therefore not seen in large groups of cells. Cells are usually induced to undergo apoptosis in 
response to an imbalance in tissue homeostasis and apoptosis is characteristically seen during 
embryonic development. In response to disease, apoptosis also acts to eliminate cells affected 
by cancerous growth as well as viral infections like HIV (Kam and Ferch, 2000). Wherever it 
is involved, the main function of apoptosis remains to induce physiological death in cells that 
pose a threat to the body (Elmore, 2007).  
 
1.5.2. Caspase structure and activation 
The apoptosis pathways, whether intrinsic or extrinsic, are largely dependent on the cleavage 
of a family of proteases termed caspases (Chowdhury et al., 2008). The first caspase known 
to result in apoptosis, however, was identified in C. elegans as the cell death gene and called 
ced-3 (Kumar, 2007). Since then, the number of mammalian caspases that have been 
identified has risen to 15 of which 11 have been identified as human (Nicholson, 1999).  
Caspases are cysteinyl aspartate proteinases and cleave substrates after the Asp residue 
(Kumar, 2007). The first member of this family to be identified was the protease required for 
the maturation of pro-IL-1, at the time called interleukin-1-converting enzyme (ICE). It 
was subsequently cloned and called caspase-1 (Chowdhury et al., 2008).  
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Caspases are synthesised as catalytically inactive zymogens known as pro-caspases, before 
being cleaved by other caspases to become active, mature caspases, as demonstrated by 
Figure 1.7. The small and large subunits of active caspases are derived from the inactive pro-
domain. The large subunit contains the proteolytic region, including the cysteine and histidine 
residues of the active site. Residues S4-S1 from both subunits make up the substrate-binding 
cleft (Nicholson, 1996), similar in structure to the HIV-1 protease mentioned earlier.  
 
  
 
 
 
 
 
 
Figure 1.6. X-Ray crystal structure of caspase-3 in complex with a substrate-based inhibitor (Adapted 
from Nicholson, D.W., 1999). 
 
Caspases are divided into two groups, namely initiator caspases and effector caspases. 
Initiator caspases function to activate effector caspases, which make apoptosis possible 
(Boatright and Salvesen, 2003). 
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Figure 1.7. Activation of a pro-caspase into a mature, active caspase (Chowdhury et al., 2008). 
 
Mammalian, apoptotic caspases, apart from having differences in function, also differ in their 
prodomain structure. Initiator caspases have long pro-domain structures at the N-terminus, 
comprised of a death effector domain (DED) or a caspase recruitment domain (CARD) (Chen 
and Wang, 2002). These include caspases 1, 2, 4, 5, 8, 9, 10, 11, 12 and 13.  Effector 
caspases, however, caspases 3, 6, 7 and 14 possess short pro-domains (Nunez et al., 1998). 
Caspase active sites are, however, highly conserved among both effector and initiator 
caspases, as demonstrated in Figure 1.8. 
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Figure 1.8 Amino acid sequence alignment of caspases, showing active site conservation (Adapted 
from Cohen, 1997). 
 
1.5.3 Caspase-3 and its role in apoptosis  
Caspase-3, also termed CED-3 or CPP32, was the first identified effector caspase found to be 
involved in apoptosis of mammalian cells (Kang et al., 2008). Caspase-3 is known to be one 
of the most frequently activated caspases involved in apoptosis and has therefore been known 
to play a critical role in the process as a whole (Porter and Jänicke, 1999). The activation of 
this effector caspase occurs via two pathways, namely the extrinsic and the intrinsic 
pathways. In the extrinsic pathway, death receptors result in the formation of a death-
inducing signaling complex (DISC), which results in the accumulation of active caspase-8. 
Caspase-8 then results in the activation of the effector caspase-3, thereby resulting in 
apoptosis. In the intrinsic pathway, which is mediated by the mitochondria, cytochrome c is 
released. Upon release of cytochrome c, a cytoplasmic complex, the apoptosome, is formed, 
which is responsible for the activation of procaspase-9. Once again, the effector caspase, 
caspase-3, is activated and this results in apoptotic cell death (Chowdhury et al., 2008). 
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1.5.4 Caspase-3 as a death-inducing protein for HIV-1 infection 
As mentioned in section 1.5, a strategy that employed caspase-3 as a death-inducing protein 
for HIV-infected cells was demonstrated by Vocero-Akbani et al in 1999. They suggested a 
strategy that makes use of the function that HIV-1 protease has in cleaving the gag-pol 
protein to produce new viral proteins (Haseltine, 1991). The current treatment regime for 
HIV-1 infection includes, amongst others, inhibitors of HIV-1 protease to combat viral 
replication. In the strategy by Vocero-Akbani and colleagues, however, the protease was used 
to trigger apoptosis in cells representing HIV infection. This was achieved by site-directed 
mutagenesis of caspase-3 by replacing caspase-3 cleavage sites with HIV-1 protease cleavage 
sites. Caspase-3 and HIV-1 protease are both aspartic proteases, and are similar in both 
structure and mechanism of function. This strategy therefore resulted in the cleavage of 
caspase-3 into its active form in the presence of HIV-1 protease, which subsequently resulted 
in the activation of apoptosis in cells containing HIV-1 protease. It can therefore be 
concluded that this strategy successfully demonstrated the destruction of cells containing 
HIV-1 protease by apoptotic cell death (Vocero-Akbani et al., 1999).  
The study is not, however, without limitations. One such limitation is that, due to the use of 
the transactivator of transcription (TAT) protein transduction domain, the mutant caspase-3 
was not targeted to cells, and as a result, was non-specific.  
Protein transduction domains, also called protein derived cell penetrating peptides (CPPs), 
promote cellular internalization, but are not specific (Zorko and Langel, 2005). Non-specific 
delivery of a therapeutic is not ideal, since it reduces the efficacy thereof. One way of 
combating the aforementioned limitation is by targeted delivery of the mutant caspase-3.  
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Many strategies for delivery exist, but in this study, nanotechnology was used as a means of 
targeted delivery of the therapeutic. Nanotechnology offers an exciting new solution to the 
problems associated with drug delivery, and is explored further in the next section.  
 
1.6 Nanotechnology 
Nanotechnology can be described as the study, design, synthesis, creation, utilisation or 
manipulation of structures in the nano size range (1x10
-9
 of a meter) to produce desired 
effects (Salamanca-Buentello et al. 2005; Maynard, 2007). Aside from setting the research 
world abuzz, nanotechnology has also been hailed in popular press as the latest major 
technological breakthrough. Working in the nano size range allows scientists to explore a 
world that has, until recently, remained unknown.  
The nanotechnology hype started in the 1990’s, when Eigler and Schweizer had the letters 
IBM printed on a nickel substrate using only 35 xenon atoms (Eigler and Schweizer, 1990). 
This was the first work done in the nano size range. However, the concept of working at an 
atomic scale was first unveiled in a Nobel laureate’s lecture in the year 1959. When the 
reknowned physicist, Richard Feynman, talked in his lecture about manipulating atoms at the 
nano level, he postulated that it was indeed possible to work at an atomic scale. He also stated 
that at the time, science had not been able to put it in practice, but that in the future, it would 
become possible (Feynman, 1959). Since then, nearly 50 years into the future, the technology 
is being utilised in a wide range of applications. This ranges from enhanced energy 
production and agricultural activities to improved food processing, biomedical applications 
(Salamanca-Buentello et al., 2005). 
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The nanostructure era started with the development of liposome technology by Bangham et al 
in 1965. The development of semiconductor quantum dots by Eskimov et al in 1982 soon 
followed and later, in 1985, the discovery of fullerenes by Smalley et al. The discovery of 
starburst polymers (later identified as dendrimers) came in that same year (Tomalia et al., 
2007). The identification of single-walled carbon nanotubes (SWCNT) came in 1991 (Ferrari, 
2005) and very soon, structures in the nano size range were the order of the day. Among 
these nanostructures also emerged the development of colloidal gold nanoshells or 
nanoparticles. The first known synthesis of pure colloidal gold was performed by Michael 
Faraday in 1857, which was prepared by reducing gold chloride with phosphorus (Edwards 
and Thomas, 2007). 
According to the National Nanotechnology Initiative (NNI) in the US, the ability to develop 
and manipulate materials and devices at the nanoscale will contribute roughly $1 trillion 
dollars to the US economy by 2015 (Hood, 2004). This is a large figure when one considers 
how “new” the field really is. Although the field is still in its infancy, a number of 
nanotechnology-based strategies have been developed. The following table demonstrates 
nanotechnologies that have been approved or are under review by the Food and Drug 
Administration (FDA) of the United States of America. 
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Table 4. Some nanoparticle-based pharmaceuticals approved or under review by the FDA (Adapted 
from Bawa, R., 2008). 
 
Product name Active 
ingredient 
Company Approved 
indication 
Approval date 
Doxil Caelyx Pegylated 
doxorubicin 
liposomes 
Orthobiotech 
Schering-
Plough 
Metastatic 
ovarian cancer 
November 
1995 
Abraxane Paclitaxel 
nanoparticles 
Abraxis  
BioScience 
AstraZeneca 
Metastatic 
breast cancer 
January 2005 
DaunoXome Daunorubicin 
citrate 
liposomes 
Gilead Sciences Kaposi’s 
sarcoma related 
to HIV 
infection 
April 1996 
VivaGel Dendrimer gel StarPharma 
Holdings 
Vaginal 
microbicide for 
HIV prevention 
IN TRIALS 
Aurimmune Gold particles 
coupled to TNF  
CytImmune 
Sciences 
Solid tumours IN TRIALS 
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1.6.1 Nanotech to biotech: biological applications of nanotechnology 
Biologically speaking, although nanotechnology has applications in numerous fields and 
industries, its application in medicine, termed nanomedicine, is undoubtedly amongst the 
most important (Park et al., 2007). Research prospects and advances in nanotech in the 
medical field include targeted drug delivery, disease detection, cellular imaging as well as 
sensor technology (Kubik et al., 2005). Since biological processes operate under the control 
of nanoscale processes, it only makes sense that nanotechnology and biology should form a 
convergence of sorts (Hood, 2004). Most biological components range between 1 and 100 nm 
in size, the exact size range that defines nanotechnological processes (Roco, 2003), providing 
an ideal arena for nanotechnology to be applied. Nanostructures that are currently being 
researched in the field include dendrimers, SWCNT, liposomes, micelles, semi-conductor 
quantum dots and colloidal nanoparticles. The following sections will demonstrate the 
application of these structures as well as their advantages and pitfalls. 
1.6.1.1 Dendrimers 
Dendrimers, or dendritic polymers, were first synthesised in 1985 by Tomalia et al. In this 
paper, they describe dendrimers to be starburst, hyperbranched macromolecules that emerge 
from a central core. They are generally made up of both carbohydrates and amino acids 
(Cloninger, 2002). The dendritic branches were seen as an ideal opportunity for the additions 
of various functional groups, as demonstrated by Figure 1.9. Due to their size, the high level 
of branching and its globular nature, dendrimers soon became of great interest as a scaffold in 
the field of drug delivery (Gillies and Frechet, 2005). In the cancer research arena, 
dendrimers carrying anti-cancer nucleotides were successfully delivered to various cancer 
cell lines (Ferrari, 2005). Since its synthesis, a vast amount of research has been conducted 
for various applications of dendrimers.  
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Aside from their application to drug delivery, they have also been applied as magnetic 
resonance contrast agents to improve MRI, in vitro diagnostics for determining heart muscle 
damage as well for the treatment of burns (Klajnert and Bryszewska, 2001). 
There are, however, a number of challenges related to dendrimers. Firstly, dendrimers that 
are currently synthesised do not remain in circulation long enough to be effective as drug 
delivery vehicles. Another problem, that initially seemed to be an advantage, is that 
dendrimers have a globular structure, making steric hindrance a problem for the attachment 
of different proteins or peptides (Gillies and Frechet, 2005). Finally, dendrimers, like most 
other nanoparticles, still present a huge barrier with regard to toxicity. Since they have not 
been used in long term studies, the long term effects and toxicology of these particles are not 
well documented (Yiyun and Tongwen, 2005).  
 
 
 
 
 
 
Figure 1.9 Example of dendrimer acting as drug targeting molecule (Adapted from Gillies and 
Frechet, 2005). 
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1.6.1.2 Carbon nanotubes 
Single or multi-walled carbon nanotubes can be defined as tubular structures, seen in Figure 
1.10, in the nano size range (Yih and Al-Fandi, 2006). These structures are usually grown on 
glass or quartz substrates, in the presence of a nickel catalyst. Nanotubes can vary in size 
between 30 and 150 nm in diameter and are surprisingly strong for their size. They have a 
tensile strength 100 times that of steel, indicating that these tiny structures are very strong 
(Kubik et al., 2005).  
Due to the rigid nature of these tubes, they have been exploited in various aerospace and bone 
surgery applications. Though these structures, given their small size and electrical properties 
(Kubik et al., 2005), would seem highly applicable to biological systems, research has 
suggested otherwise. According to a study done by Shvedova et al. in 2004, single wall 
carbon nanotubes have adverse effects in rodents. A suspension of carbon nanotubes 
administered to mice and rats resulted in pulmonary inflammation, granuloma formation as 
well as mortality. During in vitro studies, the result was not much different. Carbon 
nanotubes caused oxidative stress in cell, indicated by free radical formation and the 
depletion of antioxidants. Even though a separate study, during which radiolabeled carbon 
nanotubes were administered to rodents, showed intact renal excretion, the safety and toxicity 
of carbon nanotubes is a major challenge for use in biomedical applications.   
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Figure 1.10 Single wall carbon nanotube structures (Adapted from Mamalis, A.G., 2007). 
 
1.6.1.3 Liposomes  
Liposomes were one of the first nanostructures to be applied in industry, having been around 
for nearly 35 years (Ferrari, 2005). Comprised of phospholipids and cholesterol, lipid-based 
vesicles such as liposomes and micelles have the potential to become the superstars of drug 
and gene delivery. In the past, liposomal development was hindered by the inability to 
understand how the body processes them. Lipoidal vesicles can accommodate a variety of 
substrates in their spaces, are capable of targeted delivery, facilitate slow release and also 
prevent degradation by enzymes (Sofou and Sgouros, 2008). A number of liposome 
formulations have been developed for various drug delivery applications, as can be seen in 
Figure 1.11. Due to these capabilities, drugs such as doxorubicin have been successfully 
encapsulated in a liposomal vesicle for the treatment of Kaposi’s sarcoma (Ferrari, 2005). 
Lipid-based nanovectors such as liposomes and micelles have the advantage of being very 
small, allowing them to accumulate in areas with leaky vasculature, such as tumour tissue 
(Torchilin and Lukyanov, 2003). To facilitate targeted drug delivery, antibodies could easily 
be attached to the liposome surface (Sofou and Sgouros, 2008).  
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Other useful applications of liposomes in recent years have also included cosmetic 
applications such as wrinkle reduction and acne treatment. The micelle, another lipid-based 
structure, is very similar to liposomes, but have the disadvantage of having lower 
encapsulation ability in comparison to liposomes (Samad et al., 2007). Even though 
liposomes have so many advantages, a number of challenges do exist. Since polar drugs and 
drugs without charge are not encapsulated, the ability to deliver material to cells is rather low. 
When one considers the requirements for pharmaceutical use, liposomes do not have a long 
shelf life, something that would be considered crucial in the pharmaceutical industry. The 
long-term effects of these liposomal vesicles are also unknown (Soloman and Gabizon, 
2008), leaving the door wide open for toxicity.  
 
 
 
 
 
 
 
Figure 1.11 Primary types of liposomes used in various drug delivery applications (Adapted from 
Storm and Crommelin, 1998). Conventional liposomes remain either neutral or anionic in charge. 
Stealth liposomes refer to polymer-coated liposomes that exhibit increased circulation times. Targeted 
liposomes or immunoliposomes have antibodies which target them to antigens. Cationic liposomes 
refer to positively charged liposomes. 
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            1.6.1.4 Semi-conductor quantum dots 
In the ever-growing field of nanotechnology, semi-conductor nanocrystals have gained 
popularity for their inimitable optical and electronic capabilities (Jaiswal et al., 2003). In 
comparison to existing nanostructures, these particles seem to possess properties that the 
others do not, standing them in good stead for application in industry.  Theoretically, semi-
conductor quantum dots can be described as nanocrystals that have been synthesised and 
dispersed in a solvent (Alivisatos et al., 2005). Their synthesis is usually facilitated using 
precursor materials such as cadmium oxide (CdO) and in order to control the size thereof, 
nanocrystals are grown by means of the Ostwald process. This entails a ripening process 
during which small nanocrystals are broken up into tiny atoms and these atoms then form the 
basis for the synthesis of larger crystals (Chan et al., 2002).  
Semiconductor nanocrystals in the 10-15 nm range seem to be of more interest to researchers 
in the field of biology as a result of their size and optical properties. At these sizes, there are 
hardly any limitations with regard to kinetics and binding. Steric hindrance also seems to be 
avoided in this range (Gao et al., 2007). Their unique optical properties are made possible by 
a process called ‘quantum confinement’. This phenomenon results in the increase in spacing 
between atomic energy levels as the nanocrystal size is decreased. The most significant 
properties of these nanocrystals are their increased levels of fluorescence and increased 
resistance to photobleaching (Jaiswal and Simon, 2004).  
Another feature of semiconductor quantum dots over other organic fluorophores is the ability 
to apply them to multiplexing experiments for coding entire libraries, whereas organic dyes 
can detect only one gene, protein or peptide at a time (Gao et al., 2004).  
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Up until the advent of quantum dots, the only available probes were organic dyes. These, 
although effective, are much more susceptible to photobleaching and also undergo a process 
where fluorescence is switched on and off, called blinking (Jaiswal and Simon, 2004). This 
makes quantum dots particularly useful in the field of cellular and molecular imaging and 
recent experiments show that quantum dots can be effectively employed in the tracking and 
detection of organs, cells, organelles, proteins and mRNA (Alivisatos et al., 2005; Jaiswal 
and Simon, 2004; Gao et al., 2004). 
 
 
 
 
 
Figure 1.12 Colour variation of CdSe/ZnS semiconductor quantum dots after being excited with a 
near UV source (Adapted from Chan et al., 2002). The emission spectrum increases from left to right, 
demonstrating various colours. The extreme left (dark blue) vial has an emission maximum value of 
443 nm, while the vial on the extreme right has an emission maximum value of 655 nm.   
 
Although quantum dots have proven to be a useful tool in the field of nanotechnology, there 
are a number of concerns regarding their toxicity in humans as well as their eradication from 
the body. Most of the semiconductor quantum dots used in biological applications are 
synthesised from cadmium and selenium (Gao et al., 2004). Both of these are known to be 
toxic to humans in ionic form. Experiments by Derfus et al. in 2004 show that upon UV 
irradiation, cadmium is oxidised to Cd
2+
 ions and results in cell death via apoptosis. If one 
were to apply quantum dots to biological platforms such as drug delivery and imaging, they 
would need to be compatible with a biological environment.  
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To this end, researchers have looked towards adding certain functional groups. Chemical 
groups such as polyethylene glycol (PEG) and mercapto-undecanoic acid have been added to 
cadmium-based quantum dots to make them soluble in aqueous biological environments 
(Shiohara et al., 2004; Alivisatos et al., 2005; Yu et al., 2006).  
 
 
 
 
 
Figure 1.13 Structure of a quantum dot comprised of a Cadmium Selenide core and a Zinc Sulphide 
shell, which improves quantum yield and photostability (Adapted from Jaiswal and Simon, 2004). 
 
One other way to protect the cadmium cores of CdSe quantum dots from oxidation is by the 
addition of a ZnS shell, as can be seen in Figure 1.13. This method also protects the quantum 
dots from interaction with biological media. Additionally, the coating of nanocrystals with 
ligands is also employed as a means of solubilising them, as well as creating a platform for 
the conjugation of biomolecules (Medintz et al., 2005). In experiments performed by Gao et 
al., quantum dots were conjugated with amphipathic triblock polymers to protect the inner 
core from the environment and PEG was used to aid with biocompatibility. This allowed 
successful tracking and mapping of lymph nodes in live animals (Gao et al., 2004). 
Even though these extra functionalities do protect the cadmium cores from being exposed, 
very little is known about the fate of quantum dots. Preliminary work suggests that they are 
eradicated from the body via kidney excretion and slow filtration (Gao et al., 2004).  
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These have not yet been supported by scientific evidence and a great deal more research is 
needed to determine the endpoint of these nanostructures before they can be used in humans. 
However, a number of advances have been made with the use of quantum dots. Due to their 
increased fluorescence and size, colloidal nanocrystals have successfully been used in cellular 
tracking, cell motility, imaging and detection experiments (Alivisatos et al., 2005). 
 
1.6.2 Gold nanoparticles 
 
From ancient Egypt to the California Gold Rush, there is no doubt that the discovery and 
production of gold has a colourful history. Through the years, gold has been developed as a 
form of currency and also made into jewellery, as an indication of wealth. Gold has long 
since provided us with a currency for trade and is currently one of the most valuable 
commodities in South Africa. The first appearance of gold nanoparticles, however, dates back 
to ancient times when they were used to produce stained glass (Sperling et al., 2008). Aside 
from its economic value, gold has also been known to have certain medical applications. In 
the late 1930’s, for example, gold salts were found to dramatically improve the condition of 
patients suffering from rheumatoid arthritis. Back then, however, no precautionary measures 
were taken to prevent gold from causing a toxic response in patients. Due to this toxic 
response, mortality resulted in a small number of these patients (Sashin et al., 1939). This 
initial interest in gold has led to the development and use of gold in small, colloidal clusters 
in the form of nanoparticles. 
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1.6.2.1 Preparation of biocompatible gold nanoparticles 
The first method for synthesising colloidal gold was introduced by Faraday in 1857 and 
reworked by Turkevitch and colleagues in 1951 (Turkevitch et al., 1951). The method 
employed was the citrate reduction of tetrachloroauric acid (HAuCl4) in water, which lead to 
the synthesis of 20 nm particles (Daniel and Astruc, 2004).  
Another method, the two-phase system, was first described by Wilcoxon et al in 1993 
(Wilcoxon et al., 1993) and then adjusted by Brust et al in 1994. This system employs the 
transfer of gold chloride from an aqueous solution to toluene by means of 
tetraoctylammonium bromide. The second phase, the reduction, is facilitated by sodium 
borohydride with dodecainethiol as the supplementary agent (Brust et al., 1994). More 
recently, however, researchers have developed a method for the large-scale synthesis of 
nanoparticles at room temperature. These particles can be synthesised in a simple way so that 
they are of nearly equal molar mass, and the size is controllable by the amounts of 
tetrachloroauric acid added (Polavarapu and Xu, 2009). These size and structure of these 
particles is shown in Figure 1.14. 
 
 
 
 
 
 
Figure 1.14 Transmission Electron Microscopy (TEM) image of biocompatible gold nanoparticles 
prepared by citrate reduction of gold chloride at room temperature (Polavarapu and Xu, 2009). 
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There are a number of characteristics of gold nanoparticles, as mentioned before, that make 
them an attractive choice for use in biological applications. One in particular is the ability to 
make these particles biocompatible by the addition of certain functional groups or 
biomolecules. This was demonstrated in a study by Tshikhudo and colleagues in 2004. In this 
study, thioalkylated polyethylene glycol ligands were designed and synthesised to generate 
gold nanoparticles that are soluble in aqueous environments (Tshikhudo, 2004). In a separate 
study by Shukla and colleagues in 2005, lysine and poly-L-lysine were used as capping 
agents to generate biocompatible gold nanoparticles (Shukla et al., 2005). Upon adding these 
ligands, the metal core of the particle is shielded from the external environment and assists in 
protecting the cellular environment from undergoing a toxic response. Apart from ligands, the 
number and type of moieties added are naturally dependent on the application for which the 
particle is needed. The ability to functionalise these gold nanoparticles with organic 
molecules therefore allows nanoparticles to interact with the biological environment so it can 
carry out its intended function.  
  
1.6.2.2 Applications of colloidal gold nanoparticles 
In recent years, the use of colloidal gold nanoparticles has become very popular indeed. By 
nature, gold is biologically inert, less toxic than other materials and generally easy to 
synthesise (Sperling et al., 2008). Colloidal gold nanoparticles have great promise in the 
development of nanoelectronic devices, biolabeling and biosensing. These are currently 
among the common applications of gold nanoparticles (Huo, 2007). A particularly useful 
characteristic of gold nanoparticles is the ability to conjugate and modify them by the 
addition of biomolecules and functional groups (Mishra et al., 2009). 
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 As demonstrated in Figure 1.15, a protein containing a poly-histidine tag can be 
functionalised to a nickel-activated nitriloacetic acid (NTA) gold nanoparticle. As a result of 
this functional ability, gold nanoparticles have been employed in a variety of fields, 
particularly in the biological sciences. Applications for gold nanoparticles include their use in 
drug and gene delivery (Moghimi et al., 2001). The ability of gold nanoparticles to interact 
with thiol groups also makes them a good choice for controlled release within the cellular 
environment and various examples of this can be observed in literature (Ghosh et al., 2008).  
 
 
 
 
 
Figure 1.15 Schematic diagram of a gold nanoparticle functionalised with Ni-NTA for conjugation to 
a poly-histidine tagged protein (Adapted from De et al., 2008). 
 
In a study by Mukherjee and colleagues in 2005, unfunctionalised gold nanoparticles 
demonstrated anti-angiogenic properties in vitro and in vivo when they were found to bind 
heparin-binding proteins. Heparin-binding proteins, such as vascular endothelial growth 
factor (VEGF), play a key role in the induction of angiogenesis. Since angiogenesis is critical 
for tumour development and progression, it stands to reason that anti-angiogenic compounds 
could be utilised to inhibit the growth of tumours (Mukherjee et al., 2005). In 2005, a study 
by El-Sayed and colleagues demonstrated the imaging capabilities of gold nanoparticles.  
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In this study, dark-field microscopy was used to differentiate cancerous cells from non-
cancerous cells using gold nanoparticles functionalised with an epithelial cancer cell 
antibody, EGFR (El-Sayed et al., 2005). With regard to drug delivery, a study performed by 
Choi and colleagues in 2010 demonstrated that gold nanoparticles functionalised with human 
transferrin were able to enhance the intracellular delivery of therapeutic agents (Choi et al., 
2010).  
1.6.2.3 Nanotechnology-based treatment strategies for HIV infection 
Nanotechnology had received much attention in the area of disease. It has been extensively 
used to target cancer, with a number of therapeutics already on the market. One of the most 
challenging diseases with regard to developing therapeutics, however, remains HIV/AIDS. 
Although humanity has been battling with this disease for 30 years, treatment strategies have 
not changed dramatically. With this in mind, and owing largely to its novelty, researchers 
have looked to the field of nanotechnology for a solution (Nie et al., 2007). 
The HIV virus measures approximately 150 nm in size and is therefore, in itself, a 
nanostructure. Due to the size, biocompatibility, toxicity profiles and the possibility of 
targeted payload delivery, nanotechnology has offered an attractive solution to the treatment 
of HIV/AIDS (das Neves et al., 2010). A study by Bender and colleagues in 1996 
demonstrated that polyhexylcyanoacrylate-based (PHCA) nanoparticles increased the 
efficacy of antiretroviral drugs such as saquinavir and zalatabine (Bender et al., 1996). 
Another study, performed by Shah and Amiji in 2006 demonstrated a ten-fold increase in the 
cellular uptake of saquinavir when conjugated to a nanoparticle (Shah and Amiji, 2006).   
 
 
 
 
 
41 
 
Though most of the studies that have been done rely on the use of antiretrovirals conjugated 
to nanomaterials, a study performed by Elechiguerra and colleagues in 2005 demonstrated 
that silver nanoparticles with various surface chemistries were able to inhibit the binding of 
HIV to host cells (Elechiguerra et al., 2005). Figure 1.16 demonstrates these silver 
nanoparticles bound to HIV-1. A similar study was done in 2008, utilising multivalent gold 
nanoparticles this time, demonstrating inhibition of HIV fusion to host cells (Bowman et al., 
2008).  
 
 
 
 
 
Figure 1.16 High angle annular dark field (HAADF) image of silver nanoparticles bound to an HIV-1 
virus (Adapted from Elechiguerra et al., 2005). 
 
The aforementioned research suggests that there exists a definite opportunity for the 
application of nanotechnology in developing treatment strategies for HIV infection. With the 
use of nanotechnology and the strategy employed by Vocero-Akbani and colleagues, we aim 
to demonstrate the targeted destruction of HIV-infected cells towards a therapeutic treatment 
of this devastating disease. 
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1.7 Objectives of the project  
 
HIV/AIDS and other incurable diseases have been devastating the quality of life of millions 
the world over for many years. Since the advent of nanotechnology, many developments have 
been made in the food, information technology and pharmaceutical industries. The aim of this 
study is to develop a nanotechnology-based death-inducing delivery system for the 
destruction of HIV-infected cells.  
 
An in vitro cell model system representing an HIV infected cell will be generated by co-
transfecting CHO (Chinese Hamster Ovary) cells with two DNA plasmids, which contain the 
human CD4 gene as well as the HIV-1 protease gene. As a result these mutant CHO cells will 
resemble HIV-infected cells in two ways: the cells will express human CD4 receptor on their 
surface and HIV-1 protease in the cytosol. This study will develop a death-inducing system 
similar to the strategy developed by Vocero-Akbani et al. (Vocero-Akbani et al., 1999), with 
the added advantage of being a targeted delivery system.  
The HIV-infected cell model system described above will be used to demonstrate that gold 
nanoparticles bi-conjugated with a CD4 targeting peptide (Slepushkin et al., 1996) and a 
mutant form of caspase-3 (that is only cleavable by HIV-1 protease) can be specifically 
delivered to CD4 expressing cells and induce cell death in these cells through the activation 
of apoptosis.  
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Using genetic engineering tools, the apoptosis-inducing protein, caspase-3, will be modified 
as described by Vocero-Akbani et al., and will therefore only be cleavable by HIV-1 
protease. This protein will be recombinantly expressed in and purified from E.coli. The 
purified protein will be conjugated to gold nanoparticles and delivered to mammalian cells. 
These cells will express CD4 on their surface, since HIV primarily infects CD4 expressing 
cells. The CD4-expressing cells will also be transfected with HIV-1 protease. The conjugated 
nanostructure will then be targeted to these cells by the addition of a CD4 targeting peptide 
that specifically recognises CD4
+
 cells. Upon uptake of the nanostructure by the “HIV-
infected” cell, the mutant caspase-3 will be activated by HIV-1 protease, which will cleave it 
from its inactive form into active caspase-3. This will result in apoptosis of that particular 
cell, without causing damage to surrounding cells, much like destroying HIV-infected CD4 
cells and leaving uninfected CD4 cells unharmed in a clinical scenario. This strategy should 
result in a decrease in the number of HIV-infected cells, and thereby reduce viral load. 
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Figure 1.17 Schematic illustration of the targeted destruction of HIV-1 protease and CD4 expressing 
cells. 
 
The application of nanotechnology to biological systems is an area of scientific research that 
is still in its infancy and will require much more research. This study intends to answer some 
of the questions surrounding nanotechnology in biology, and possibly move towards the use 
of nanotechnology in the treatment of disease. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 General Chemicals and Reagents 
40 % 37.5:1 Acrylamide:bis-acrylamide    Bio-Rad  
7-Amino-Actinomycin D (7-AAD)            BD Biosciences 
Agarose              Promega   
Ammonium persulphate (APS)              Merck   
Ampicillin                                                                       Roche   
APOPercentage
™
 dye       Biocolor 
Bacteriological agar                                                        Merck   
Boric acid                                                                        Merck   
Bovine serum albumin (BSA)                                         Roche   
Bromophenol blue                                                           Sigma   
Buffer saturated phenol                                                   Invitrogen   
BugBuster
® 
Ni-NTA His•Bind® Purification Kit  Novagen 
Caspase-3 antibody        Cell signaling technology 
Cesium Chloride (CsCl)      Roche 
Cytobuster
™
 Protein Extraction Reagent    Novagen 
Chloroform                                                                      BDH  
Coomassie Brilliant Blue R-250                                      Sigma   
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Dimethyl sulphoxide (DMSO)                                        Sigma  
Dithiothreitol (DTT)                                                        Roche   
Ethylene diamine tetra acetic acid (EDTA)                     Merck   
Ethanol                                                                             BDH  
Ethidium bromide (EtBr)                                                     Promega 
Fluoroshield™ with DAPI (4',6-diamidino-2-phenylindole) Sigma 
G-418 Solution        Roche 
Glacial acetic acid                                                            Merck   
Glucose                                                                             BDH  
Glutathione                                                                       Sigma   
Glycine                                                                              BDH  
Hydrochloric acid                                                              Merck   
Imidazole          Sigma 
Isopropyl β-D-thiogalactopyranoside (IPTG)                   Promega   
Isopropanol        Merck 
MES [2-(N-morpholino)ethanesulfonic acid]   Sigma 
Methanol                                                                            Merck   
Metafectene™ Pro Transfection Reagent   Biontex 
Mowiol         Sigma 
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Ni Sepharose™ 6 Fast Flow                                              GE Healthcare   
Nickel sulphate (NiSO4)      Sigma 
Paraformaldehyde                                                              Sigma  
Phenylmethylsulphonyl fluoride (PMSF)                       Roche   
Ponceau S                                                                           Sigma  
Sodium azide                                                                      Roche  
Sodium borohydride                                                            Sigma 
Sodium chloride (NaCl)      Merck 
Sodium dodecyl sulphate (SDS)                                        Promega   
Sodium hydroxide                                                              Merck   
SuperSignal West Pico Chemiluminescent Substrate Thermo Scientific 
Sybr Safe DNA Gel Stain             Invitrogen 
N, N, N', N'-Tetra methylethylene-  
diamine (TEMED)                                                               Promega   
Tetrachloroaurate (gold chloride)                                        Sigma 
Tris [hydroxymethyl] aminoethane (Tris)                      BDH  
Triton X-100 (iso-octylphenoxypoly-  
ethoxyethanol)                                                                    Roche  
Tryptone                                                                             Merck   
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Tween-20 (Polyoxyethylene [20] sorbitan)                         Merck 
WST-1                Roche 
Xylene cyanol                                                                     BDH  
Yeast extract                                                                       Merck   
 
Restriction endonucleases were supplied by New England Biolabs, Fermentas or Roche 
Diagnostics. T4 DNA ligase was obtained from Promega. ExSel Taq DNA polymerase was 
obtained from Jain Biologicals. DreamTaq
™
 Green PCR Master Mix (2 X) and Pfu DNA 
Polymerase were supplied by Fermentas. Unstained and prestained DNA and Protein 
Molecular Weight Markers were supplied by Fermentas. 
 
2.2 Buffers and solutions  
10 X TBE 
0.9 M Tris, 0.89 M boric acid, 0.032 M EDTA; stored at room temperature. 
6 X Glycerol DNA Gel-loading Buffer 
30 % glycerol, 0.25 % Bromophenol blue and 0.25 % Xylene cyanol.  
10 X Tris EDTA (TE) 
10 mM Tris-HCl, 1 mM EDTA, pH 7.5.  
DNA Loading buffer 
0.25 % Bromo-phenol-blue, 0.25 % xylene cyanol, 30 % glycerol.  
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Diethyl pyrocarbonate (DEPC) water 
2 ml diethyl pyrocarbonate in 2 l distilled water; incubated at 22 °C overnight and 
autoclaved. 
GTE 
500 mM Glucose, 50 mM Tris-HCl and 10 mM EDTA, pH 8.0. 
Lysis solution 
200 mM NaOH and 1% SDS 
Neutralisation solution 
3 M KAc, pH 5.0. 
RNAse (DNase free)  
A 20 mg/ml stock solution was prepared in a buffer containing 0.1 M sodium acetate  
and 0.3 mM EDTA (pH 4.8, with acetic acid). This solution was boiled for 15 minutes  
and cooled quickly by placing it in ice water.  
Ampicillin 
100 mg/ml ampicillin in distilled water; filter sterilized. 
Ammonium persulphate (APS) 
A 10 % stock solution was prepared in deionised water.   
Cell lysis buffer 
PBS, pH 7.4, containing 1 mM DTT, 1 mM PMSF and 100 µg/ml Lysozyme. 
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Chloramphenicol 
100 mg/ml in absolute ethanol.  
Coomassie Staining Solution 
0.25 g Coomassie Brilliant Blue R 250, 45 % methanol and 5 % acetic acid.  
Destaining solution 
30 % methanol and 10 % acetic acid.  
Dithiothreitol (DTT) 
A 1 M stock solution was prepared in 0.01 M Sodium acetate, pH 5.2. This solution  
was sterilised by filtration.  
Ethylene diamine tetra acetic acid (EDTA) 
A stock solution was prepared at a concentration of 0.5 M in deionised water, pH 8.0. 
10 % Sodium dodecyl sulphate (SDS) 
10 % SDS in distilled water.  
Isopropyl β-D-thiogalactopyranoside (IPTG) 
A 1 M stock solution was prepared in deionised water. The solution was sterilised by  
filtration.  
Kanamycin sulfate 
50 mg/ml Kanamycin in distilled water.  
 
 
 
 
 
51 
 
Luria Agar 
14 g/l Bacteriological agar, 10 g/l Tryptone, 5 g/l Yeast Extract and 5 g/l NaCl. 
 Luria Broth 
10 g/l Bacto-tryptone, 5 g/l Bacto-Yeast Extract and 5 g/l NaCl.   
TYM Broth  
20 g/l bacto-tryptone, 5 g/l yeast extract, 3.5 g/l NaCl, 2 g/l MgCl2.  
Lysozyme 
A stock solution was prepared at a concentration of 50 mg/ml in deionised water.  
MES Buffer  
30 mM MES prepared in deionised water. pH 6.0. 
1X Ni-NTA Bind Buffer (used for lysis and binding) 
50 mM NaH2PO4, pH 8.0; 300 mM NaCl; 10 mM imidazole. 
1X Ni-NTA Wash Buffer 
50 mM NaH2PO4, pH 8.0; 300 mM NaCl; 40 mM imidazole. 
1X Ni-NTA Elute Buffer 
50 mM NaH2PO4, pH 8.0; 300 mM NaCl; 500 mM imidazole. 
10 X Phosphate-buffered saline (PBS) 
137 mM NaCl, 27 mM KCl, 80 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4. 
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Phenylmethylsulphonyl fluoride (PMSF) 
A 10 mM stock solution was prepared in isopropanol.   
Ponceau S staining solution 
0.1% Ponceau S in 5% acetic acid. 
Separating buffer 
1.5 M Tris- HCl pH 8.8, stored at 4 °C. 
Stacking buffer 
0.5 M Tris- HCl pH 6.8, stored at 4 °C. 
TBS (Tris-buffered saline) 
20 mM Tris-HCl and 150 mM NaCl, pH 7.5.   
 TBS-T 
TBS containing 0.1 % Tween-20.  
TBS-MT 
TBS containing 5 % low fat dried milk powder and 0.1 % Tween-20.  
Tfb1 Buffer 
30 mM Potassium acetate, 50 mM MnCl2, 0.1 M KCl, 6.7 mM CaCl2 and 15 %  
glycerol (v/v).  
Tfb2 Buffer 
9 mM MOPS, 50 mM CaCl, 10 mM KCl and 15 % glycerol (v/v).  
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Transfer Buffer 
25 mM Tris, 192 mM glycine and 20 % methanol.  
Cell culture media and reagents 
The following tissue culture media and supplements were supplied by Invitrogen: nutrient 
mixture Ham’s F12, RPMI, 100 X penicillin-streptomycin, trypsin, PBS without Ca2+/Mg2+ 
and Foetal calf serum (FCS).  Metafectene

 Pro was used as transfection reagent and was 
supplied by Biontex. APOPercentage™ apoptosis assay kit was supplied by Biocolor and 7-
AAD was supplied by BD Biosciences. G-418 solution was used as selection antibiotic and 
was supplied by Roche. 
Fluorescence microscopy mounting medium (Mowiol) 
A stock solution of Mowiol was prepared by adding 6 g of glycerol to 2.4 g Mowiol (Sigma). 
While stirring, 6 ml distilled water was added and the solution was left to stir a further 2 
hours at room temperature. After 2 hours, 12 ml of 0.2 M Tris (pH 8.5) was added. The 
solution was incubated at 50 – 60 ºC for 10 minutes to dissolve the Mowiol. Once dissolved, 
the solution was centrifuged at 5000 x g for 15 minutes to remove any undissolved solids. 1 
ml aliquots were stored at - 20 ºC. 
Paraformaldehyde Fixative 
16 g paraformaldehyde was dissolved in 80 ml deionised water by stirring at 70 °C (in fume 
cupboard). One drop of 2 M NaOH was added. The solution was cooled to room temperature 
and the volume adjusted to 100 ml with deionised water. This solution was filter sterilised 
through a 0.45 micron filter and a 100 ml 2 X PBS was added.   
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2.3. Gel electrophoresis of DNA  
  
2.3.1 Gel preparation and electrophoresis  
Gels were prepared by adding the required volume of 1 X TBE to the appropriate mass of 
electrophoresis grade agarose. The agarose was then boiled and cooled to 55 °C. Ethidium 
bromide was added to the agarose solution to a final concentration of 0.5 μg/ml. This was 
then set in the appropriate gel caster, using 10-well combs to make wells. All gels were 
electrophoresed in 1 X TBE at 8 V/cm. Sybr Safe DNA Gel Stain from Invitrogen™ was 
added at a 1 X concentration from a 10 000 X stock solution. 
  
2.3.2 Sample preparation  
Approximately 1 μl (0.5 vol) of DNA loading buffer was mixed with DNA in 5-20 μl and 
loaded into the wells of the gel.   
 
2.3.3 Detection of DNA  
Gels contained ethidium bromide or Sybr Safe DNA Gel Stain, thus DNA was visualized by 
illuminating the gel with wavelength UV light on a trans-illuminator. Gels used for the 
recovery of DNA were exposed to a 360 nm wavelength lamp to avoid damage to the DNA.  
 
2.3.4 Gel purification of DNA 
The appropriate sized DNA fragment was removed using a sterile scalpel blade and placed in 
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a 1.5 ml microcentrifuge tube. DNA was isolated from the gel slice using the QIAquick

 Gel 
Extraction Kit from Qiagen or the Nucleospin Extract II

 gel purification kit from Macherey-
Nagel, according to manufacturer’s instructions. In brief, the excised gel slice was incubated 
at 50 °C in binding buffer.  
Once the gel liquefied, it was passed over a silica membrane. After two wash steps, the DNA 
was collected in elution buffer and stored at – 20 °C.  
 
2.4 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated on SDS-PAGE gels. Gels were made from a 40 % of pre-mix 
acrylamide: bisacrylamide (37.5:1) (Bio-Rad). The separating gel consisted of 12 to 16 % 
acrylamide: bisacrylamide (37.5:1), 0.375 M Tris-HCl, pH 8.8, 0.1 % SDS, 0.5 %, 
ammonium persulphate and 0.1 % TEMED. The stacking gel consisted of 4 % acrylamide: 
bisacrylamide (37.5:1), 0.125 M Tris-HCl, pH 6.8, 0.1 % SDS, 0.5 % ammonium persulphate 
and 0.1 % TEMED. The samples were mixed with an equal volume of 2 X Sample Buffer, 
boiled for 5 min, centrifuged for 10 minutes at 10 000 x g, and electrophoresed in 1 X SDS 
Electrophoresis Buffer at 100 V/cm (constant voltage) for about 25 minutes using the Mini 
Protean IIelectrophoresis system (Bio-Rad). The voltage was increased to 150 V/cm 
(constant voltage) when the bromophenol blue dye front reached the separating gel. 
Electrophoresis was stopped when the bromophenol blue dye front reached the bottom of the 
gel. The gel was incubated in Coomassie Staining Solution for 30 minutes and then incubated 
in De-staining solution, until suitably de-stained.  
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2.5 DNA quantification 
DNA was quantified using a 2 l sample of DNA on the NanoDrop ND 1000. Software 
version 3.1.2 was used to determine the concentration of nucleic acids at a wavelength of 260 
nm.  
 
2.6 Small-scale preparation of plasmid DNA  
Plasmid DNA was prepared using the Wizard® Plus SV Minipreps Kit from Promega 
according to manufacturer’s instructions. In brief, 30 ml cultures containing the appropriate 
antibiotic and the plasmid DNA of interest, were grown overnight at 37 °C with shaking. 
Bacterial cells were then collected by centrifugation for 20 minutes at 3000 x g. The pelleted 
bacterial cells were resuspended in resuspension buffer before cell lysis. The cells were 
centrifuged at 11 000 x g for 10 minutes to produce a cleared lysate. The lysate was then 
passed over a column to capture the DNA. The column was washed twice in a wash solution 
containing 95% ethanol and the DNA was eluted with 1 X TE.  
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2.7 Large-scale preparation of plasmid DNA using CsCl/EtBr fractionation 
Part I: Nucleic acid purification 
Bacterial cultures (500 ml each) containing the appropriate antibiotic and the plasmid DNA 
of interest were grown in sterile polypropylene tubes overnight at 37 °C with shaking. 
Bacterial cells were collected by centrifugation at 4 500 x g for 10 minutes at 4 °C, using a 
Beckman centrifuge with a JA-14 rotor. The bacterial pellet was resuspended in 4 ml of GTE 
buffer and incubated on ice for 10 minutes. Cell lysis was facilitated by the addition of 8 ml 
of lysis solution and the solution was gently swirled while being incubated on ice for 10 
minutes.  Neutralisation solution at a volume of 6 ml was added and mixed gently to 
neutralise the alkali, and the mixture was incubated on ice for 10 minutes. The precipitate, 
containing choromosomal DNA and cell debris, was removed by centrifugation at 4 500 x g 
for 15 minutes at 4 °C. The supernatant was filtered through glass wool and the nucleic acids 
were precipitated by the addition of 0.8 volumes of isopropanol, followed by incubation at -
20 °C for 20 minutes. The precipitate was pelleted by centrifugation at 10 000 x g for 10 
minutes at 4ºC. Plasmid DNA was separated from RNA by double CsCl/ethidium bromide 
fractionation. 
 
Part II: CsCl/EtBr fractionation 
The ispropanol pellet from the end of Part I was resuspended in 5 ml of 1 X TE. The solution 
was mixed with 4 mg/500µl EtBr and 5.75 g CsCl to give a final density of 1.61 g/ml. The 
density was checked by zeroing a 15ml tube containing 5ml of the sample in a beaker on a 
scale. 1ml of sample was removed from the tube and the density checked.  
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The 1ml was replaced and if the density was greater than 1.61 g/ml, 1 X TE was added to 
bring it down. If the density was below 1.61 g/ml, CsCl-saturated TE was added to take it up. 
The mixture was then centrifuged at 10 000 x g. The supernatant, containing the DNA, was 
made up to 5 ml with CsCl-saturated TE to give a final density of 1.61 g/ml. The supernatant 
was transferred to Quick-Seal™ ultracentrifugation tubes from Beckman and centrifuged at 
55 000 x g for 18 hours at 20 ºC in a Beckman Optima™ L-80 XP Ultracentrifuge, using the 
NVT 65.2 rotor. The plasmid DNA was visualised with a 360 nm UV illumination. After 
removing the caps from the centrifuge tubes, DNA was recovered using a 0.5 x 16 mm needle 
and 5 ml syringe. Plasmid DNA was recovered by adding an equal volume of NaCl-saturated 
isopropanol to remove the ethidium bromide. This extraction was repeated several times, 
until the pink colour from the ethidium bromide disappeared. Two volumes of water and one 
volume of isopropanol were added to precipitate the DNA. This was mixed well and 
incubated on ice for 10 min. The DNA was recovered by centrifugation at 10 000 x g for 15 
minutes. The pellet was resuspended in 1 X TE and stored -20 ºC until used. 
 
2.8 DNA Sequencing Using the ABI 310 Genetic Analyzer  
Sequencing reactions were performed using the DNA Sequencing Kit, BigDye
™ 
Terminator v 
3.0 Cycle Sequencing Ready Reaction (Applied Biosystems). The PCR  sequencing reactions 
were performed in a 20 μl final volume containing 3.2 pmol of the sequencing primer, 4 μl 
Terminator Ready Reaction mix (Applied Biosystems) and 4 μl 2.5 X Sequencing Buffer. For 
plasmid DNA templates, 500 ng of DNA was added, while the DNA concentration for PCR 
fragments was dependent on the size of the PCR fragment. For each of the reaction the 
reagents were added as follows:  
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Table 2.1. Reagent quantities for use in sequencing reaction    
Reagent Quantity 
Terminator Ready Reaction Mix 4.0 μl  
2.5 X Sequencing Buffer 4.0 μl  
Template:  
     DsDNA 200-500 ng 
Primer 3.2pmol 
De-ionized water to final volume of 20 l 
Total Volume 20 μl 
 
Reactions were carried out according to the manufacturer’s protocol. The contents of the 
tubes were centrifuged briefly. For the extension precipitation of samples in micro-centrifuge 
tubes the following was done: The entire contents of each extension reaction were aspirated 
and transferred into a 1.5 ml micro-centrifuge tube, 16 μl of de-ionized water and 64 μl of 95 
% ethanol were added to the 1.5 ml tube to precipitate the DNA. The samples were briefly 
mixed by vortexing.  
Samples were left at room temperature for 30 minutes to precipitate the extension products. 
Thereafter the tubes were placed into a micro-centrifuge and centrifuged for 20- 30 minutes 
at 10 000 x g. The supernatant was discarded. The pellet was washed twice with 250 μl of 70 
% ethanol, as follows: ethanol was added and the samples were briefly mixed by vortexing. 
The tubes were placed into the micro-centrifuge and centrifuged for 10 minutes at 10 000 x g. 
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The supernatant was carefully aspirated. After the second wash the pellet was dried at 37 °C 
for 10- 15 min. The pellet was stored at –20 °C until sequence analysis was performed on the 
ABI 310 PRISM® Genetic Analyzer from Applied Biosystems. 
 
The pellet was dissolved in 25 μl of Template Suppressor Buffer (TSR) [Applied 
Biosystems]. The sample was then heat denatured at 95 °C for 2 min. After denaturing the 
samples were then transferred immediately to ice for 5 minutes and sequencing using the ABI 
310 PRISM
™ 
Genetic Analyzer (Applied Biosystems) followed. Data was collected using the 
ABI 310 PRISM® Collection Software (Applied Biosystems) and the analysis was done 
using Sequence Analysis 3.3 Software (Applied Biosystems). Sequencing was also 
outsourced to Inqaba Biotechnical Industries (Pty) Ltd. 
 
2.9 Oligonucleotides  
The following oligonucleotides were synthesised by Inqaba Biotechnical Industries (Pty) Ltd: 
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Table 2.2. Synthesised primer sequences  
Gene  Primer sequence 
CD4 Forward Primer  5´-CGTAGAATTCTATGAACCGGGGAGTCCCTTA-3´ 
CD4 Reverse Primer A  5´-CGTACCCGGGAATGGGGCTACATGTCTTCTG-3´ 
CD4 Reverse Primer B  5´-CGTACTCGAGTCAAATGGGGCTACATGTCTTC-3´ 
p12 Forward Primer  5´-GGCGGCTCCCAGGTGTCACAGAACTATCCAATCGTG 
CAGAACCTGCAGGGCGGTGTTGATGATGACATGGCG-3´ 
p12 Reverse Primer  5´-CGAGCTACGCCTCGAG’TTAGTGATAAAAATAGAGTTC-3´ 
p17 Forward Primer  5´-CGCCATATGGGCGGCTGCACCGAACGCCAGGCTAACTTCCT 
GGGCAAAATCTGGCCAGGCGGAATATCCCTGGACAACAGTTAT
AAAATG-3´ 
p17 Reverse Primer  5´-CCGCCCTGCAGGTTCTGCACGATTGGATAGTTCTGTGACACC 
TGGGAGCCGCCTGTCTCAATGCCACAGTCCAG-3´ 
HIV-1 protease TOPO 
Forward Primer  
5´-CACCGATATGCCGCAGATTACCCTGTGG-3´ 
HIV-1 protease TOPO 
Reverse Primer 
5´-AAAGTTCAGCGTGCAGCC-3´ 
HIV-1 protease pET 
Forward Primer  
5´-CCGCCATATGCCGCAGATTACCCTGTGG-3´ 
HIV-1 protease pET R 5´-CCGCCTCGAGAAAGTTCAGCGTGCAGCC-3´ 
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2.10 Cloning vectors 
2.10.1 pGEM
®
-T Easy 
The pGEM
®
-T Easy Vector System (Promega) is used for direct cloning of PCR fragments. 
This cloning strategy utilises terminal extendase activity of Taq polymerase which adds an 
extra base (usually an adenosine) on the 3' end of PCR products (Clark, 1988).  
The pGEM
®
-T Easy Vector, as supplied for cloning by the manufacturer, contains single 3'-T 
overhangs at the insertion site, and is able to accommodate the ligation of PCR fragments, as 
indicated in Figure 2.1. 
 
 
Figure 2.1. The pGEM
®
-T Easy Vector System (Promega) for direct cloning of PCR fragments.  
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2.10.2 pGEX-6P-2 
The Glutathione S-Transferase (GST) gene fusion system (GE Healthcare) is a 4900 bp 
protein expression system, which can be used for the expression, purification and detection of 
recombinant fusion proteins produced in E. coli. (Smith and Johnson, 1988). The GST 
domain acts as an affinity tag that allows for the purification of the fusion protein by affinity 
chromatography using glutathione agarose. A number of GST fusion vectors have been 
developed. One such vector is pGEX-6P-2 (Figure 2.2).  
 
 
 
Figure 2.2. Circular map of the pGEX-6P-2 system. 
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2.10.3 pcDNA 3.1D/V5-His-TOPO
®
 
pcDNA 3. 1D/V5-His-TOPO
®
 Expression Kit (Invitrogen) is a 5514 bp vector system for 
stable and transient expression in mammalian hosts, facilitated by the human 
cytomelagovirus (CMV) promoter. Neomycin allows for antibiotic selection in mammalian 
cells. The vector has the V5 epitope as well as a polyhistidine tag to aid in confirmation of 
protein expression by Western blot analysis.  
 
 
Figure 2.3. Circular map and Restriction sites of pcDNA3.1D/V5-His-TOPO
®
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2.10.4 pEGFP-N3  
pEGFP-N3 (BD Biosciences) is used for fusion of proteins to the C-terminus of EGFP. The 
fluorescence of the native protein allows localization of the fusion protein inside a cell using 
fluorescence microscopy. It can be used to express EGFP within a cell and could also be used 
for stable tranfections within a cell line of interest. pEGFP-N3 is a 4700 bp vector system and 
encodes a GFP variant for the emission of greater fluorescence as well as higher levels of 
expression in mammalian cells. A circular map of the vector system can be seen below 
(Figure 2.4).  
 
 
Figure 2.4. Circular and restriction map of pEFGP-N3. 
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2.10.5 pET21a  
The pET-21a vector (Novagen) is a 5443 bp bacterial protein expression vector that is used 
for the expression of fusion proteins due to the presence of a C-terminal polyhistidine tag. It 
carries an N-terminal T7 Tag
®
 sequence for cloning plus an optional C-terminal His Tag
®
 
sequence for fusion construct purification. 
 
 
 
 
 
 
 
Figure 2.5. Circular and restriction map of pET21a. 
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2.11 Restriction enzyme digestion of DNA  
Restriction enzymes were used according to manufacturer’s instructions. In general, 1 μg of 
DNA was digested with 1 unit of enzyme in the appropriate buffer and at the appropriate 
temperature. Restriction enzymes were inactivated by either heating the reaction mixture at 
70 °C or 85 °C for 10 minutes.  
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2.12 Ligation of DNA 
Ligation reactions were set up according to the manufacturer’s instructions. Reactions  
were performed in 1X Ligase buffer (30 mM Tris-HCl, pH 7.8, 10 mM MgCl2, 10 mM  
DTT and 1 mM ATP) using T4 DNA ligase (Promega). 
 
Table 2.3. Volumes for ligation reactions 
Reaction component Standard Reaction Background Control 
2x Rapid Ligation Buffer, T4 
DNA ligase 
5 µl 5 µl 
pGEM®-T Easy Vector 
(50ng) 
1 µl 1 µl 
PCR product X µl - 
T4 DNA Ligase (3 Weiss 
units/ µl 
1 µl 1 µl 
Nuclease-free water to a final 
volume of 
10 µl 10 µl 
 
The samples were mixed by vortexing and then incubated at room temperature for 3 hours. 
After ligation, 100 μl of competent cells were added to the ligation mix and transformations 
were done.  
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2.13  Bacterial cultures 
 
2.13.1 Strains used 
(1). Escherichia coli MC1061 (Casadaban and Cohen, 1980):   
F−, araD139, (ara leu) 7697, ∆lacx74, galU−, galK−, hsm+, strA.  
(2). Escherichia coli BL21 Star
™ 
pLysS (DE3) (Stratagene):    
F− omp T hsdSB (rB−mB−) gal dcm rne131 (DE3) 
(3). Escherichia coli CodonPlus
®
 competent cells (Stratagene) B F– ompT hsdS (rB– mB–) 
dcm+ Tetr gal λ(DE3) endA Hte [argU proLCamr] [argU ileY leuW Strep/Specr] 
(4). Rosetta
™
2 (DE3) pLysS (Novagen) 
 
2.13.2 Cultures 
MC1061 E.coli was used to produce plasmid DNA, while BL21 Star
TM
 pLys (DE3) E. coli 
was used to express recombinant fusion proteins. E. coli was grown in Luria broth and on 
Luria agar plates with or without ampicillin. When required ampicillin or kanamycin was 
added to Luria broth and Luria agar plates to a final concentration of 100 μg/ml.  
 
All cultures were grown at 37 °C. Glycerol stocks were prepared directly from overnight 
cultures, grown under selectable conditions, by dilution of the culture with an equal volume 
of 80 % sterile glycerol. Stocks were stored as 500 µl aliquots at – 70 °C.  
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2.13.3 Preparation of competent cells for transformation 
Cells were streaked out on a Luria agar plate and incubated at 37 ºC for 16 hours. A single 
colony was picked and used to inoculate 20 ml TYM broth, which was incubated at 37 ºC 
until the optical density at 550 nm (OD
550
) reached 0.2. 100 ml of fresh TYM broth was 
added to the culture and the cells were further incubated at 37 ºC until the OD
550 
reached 0.2. 
400 ml of fresh TYM broth was added and the cells incubated at 37 ºC until the OD
550 
reached 0.5. The cells were rapidly cooled by gently swirling of the flask in ice water and the 
culture was transferred to sterile 250 ml polypropylene tubes and centrifuged at 6000 x g at 4 
ºC for 10 minutes in a Beckman centrifuge with a JA-14 rotor. The cell pellet was re-
suspended in 250 ml ice-cold Tfb1 buffer and incubated on ice for 30 minutes, followed by 
centrifugation at 6000 x g at 4 ºC for 10 minutes. The pellet was gently re-suspended in 50 ml 
Tfb2 buffer. Re-suspended cells were dispensed in 2 ml aliquots and subsequently snap 
frozen in liquid nitrogen. Aliquots were stored at - 80 ºC until required. 
 
2.13.4 Transformation  
High efficiency competent cells of 1 x 10
7
 cfu/μg were used for transformations. To each 
ligation reaction that was prepared above, 100 μl of competent cells were added. These 
samples were then incubated for 30 minutes on ice. While these samples were incubated, 2 
Luria agar plates containing either Ampicillin or Kanamycin (depending on which DNA 
vector was used) were prepared for each reaction. To the sample tubes, 900 μl Luria Broth 
without ampicillin was added and incubated at 37 °C for an hour. The plates were prepared in 
duplicate. 100 μl of each transformation was plated and then incubated overnight at 37 °C.  
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2.14 PCR 
 
2.14.1 DNA Amplification by PCR 
PCR reactions were performed in 1 X reaction buffer according to the manufacturer’s 
instructions. ExSel Taq polymerase (Jain Biologicals), Pfu DNA polymerase [Inqaba 
Biotechnical Industries (Pty) Ltd] and DreamTaq™ Green Master Mix 2 X [Inqaba 
Biotechnical Industries (Pty) Ltd] was used according to manufacturer’s instructions. The 
primers were present at 1 pmol and between 1 and 10 ng of cDNA template was used in each 
reaction. The MgCl2 concentration was 1.5 mM. PCR reactions were cycled according the 
following parameters: 
Initial denaturation at 95 C for 2 minutes 
 Denaturation at 94 C for 30 s 
 
*
Annealing for 45 s                                      x 40 cycles 
 Elongation at 72 C for 30 s 
Final elongation at 72 C for 7 minutes 
Incubation at 4 C  
*
 Annealing temperature was dependent on primer sequence. 
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2.14.2 Colony PCR 
The colonies that appeared on the plate were counted and some of the colonies were selected. 
The colonies were resuspended in 10 μl sterile deionised water (dH2O) and these were stored 
at 4 °C. Colony PCR to identify positive clones was performed to screen for recombinant 
clones. 
 
2.15 Protein Expression 
2.15.1 Expression screening of transformants  
Positive clones were selected and plasmid DNA was prepared from them. The plasmid DNA 
was then transformed in E.coli BL21 pLys S (DE3) competent cells and after overnight 
growth on Luria agar plates, a single colony was inoculated into 1 ml of appropriate media 
containing 0.3 % glucose, and 100 μg/ml ampicillin in a 1.5 ml tube. The samples were 
cultured at 37 °C for 4 hours. After incubation, the culture was split into two 0.5 ml samples. 
To the one sample (induced sample), 0.3 mM IPTG was added and both tubes were incubated 
at 37 °C. Cells were pelleted by centrifugation for 1 minute and the supernatant was 
discarded. The cells were then resuspended into 100 μl of PBS.  A volume of 20 μl of the cell 
suspension and 20 μl of 2 X SDS sample buffer were thoroughly mixed and incubated at 95 
°C for 5 minutes. The samples were then briefly vortexed and pelleted by centrifugation. 
Proteins were analysed by SDS-PAGE as described in section 2.4. 
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2.15.2. Large-scale expression of recombinant protein  
Large-scale expression was performed by an inoculation of a single colony into 100 ml of 
Luria Broth (containing 100 μg/ml ampicillin) and incubating the culture at 37 °C overnight. 
Luria Broth (900 ml containing 100 μg/ml ampicillin) was added and incubated at 37 °C until 
the OD550 was between 0.4-0.6. IPTG was added to a final concentration of 0.5 mM. The 
sample was then incubated with shaking at 37 °C for 4 hours or 30 minutes, depending on the 
protein that was being expressed. Bacteria were recovered by centrifugation at 5000 x g for 
10 minutes. The supernatant was discarded and the pellet could be stored at –20 °C until 
further use. The pellet was resuspended in 20-25 ml of Lysis buffer. Lysis was carried out by 
freezing at –70 °C for 5 min, and thawing at 37 °C for 5 min.  
The freeze thaw process was done three or more times. The protein lysate was stored at 4 °C 
until purification. Immediate purification was preferable since degradation by proteases 
(proteolysis) could occur. A concentration of 0.02 % of sodium azide was included to inhibit 
bacterial growth. 
  
2.15.3 Protein purification using BugBuster
™
 and Ni-NTA His Bind Resin 
Native purification was performed according to manufacturer’s instructions. In brief, the cell 
pellet was resuspended in BugBuster
™
 reagent containing Benzonase. The lysate was then 
centrifuged at 3 000 x g for 20 minutes. The Ni-NTA His Bind matrix was added to 1 X Ni-
NTA Bind Buffer and the resin was allowed to settle by gravity. The supernatant containing 
the soluble protein was added to the His Bind resin and mixed on a shaker for 1 hour at 4 °C.  
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The lysate was loaded onto a column and the flow-through was collected and saved for 
analysis. The column was washed with 1 X Ni-NTA Wash Buffer and wash fractions were 
collected for analysis. Protein was eluted with 1 X Ni-NTA Elution Buffer and saved for 
analysis. Protein samples were stored at 4 °C and SDS-PAGE analysis was done. Columns 
containing His Resin were stored in 10 % ethanol.  
 
2.15.4 Dialysis and storage of protein 
Upon confirmation of purified protein, the eluted samples were pooled and dialysis was 
performed using a Slide-A-Lyzer Dialysis Cassette from Thermo Scientific, with a molecular 
weight cut off of 7 kDa. MES buffer was used to dialyse the imidazole out of the protein 
sample and the dialysed protein samples were lyophilised overnight using a Virtis model 10-
020 bench lyophiliser and stored at – 80 °C.  
 
2.16 Cell culture 
2.16.1 Cell thawing and seeding 
Vials containing cells stored at -150 C were removed and briefly placed in a 37 C water 
bath, until just thawed. Cells from the vial were then transferred to a 15 ml tube containing 5 
ml complete media (containing serum and antibiotics). Cells were then centrifuged for 2 
minutes at 800 x g to pellet them, and the cell pellet was resuspended in 5 ml of complete 
media and transferred to a 25 cm
2 
cell culture flask. Cells were incubated at 37 C with 5 % 
CO2.  
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2.16.2 Media replacement 
For adherent cell lines, media was removed from the cells and discarded. Fresh complete 
media was added to cells before incubating at 37 °C with 5 % CO2. For suspension cells, cells 
were transferred to a 15 ml tube and centrifuged at 90 x g for 2 minutes. The media was 
discarded and the cell pellet was resuspended in complete media and added to a culture flask 
before incubating at 37 °C with 5 % CO2. 
 
2.16.3 Cell count 
The Countess
™
 automated cell counter from Invitrogen was used for accurate cell counts. 
 
2.16.4 Subculturing of cells 
The cell suspensions were subcultured when cultures reached confluency. Adherent cells 
were trypsinised by incubating the cells in 1 X trypsin and incubated for 2 minutes at 37 °C 
with 5 % CO2.  
The cells were then transferred to an appropriately sized sterile tube and centrifuged at 800 x 
g for 3 minutes to pellet cells. The cell pellets were then resuspended in complete media and 
subcultured into culture flasks. 
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2.16.5 Cryopreservation of cells 
Once trypsinised, cell pellets were resuspended in complete media containing 10 % DMSO. 
Cell suspensions were transferred to cryo-vials at volumes of 1.5 ml per vial. These were then 
stored at -150 C until further use.  
 
2.16.6 Morphological analysis 
Throughout the growth and treatment process, the morphology of cells was monitored with 
the use of a Nikon microscope at 20 X magnification. Images were captured using a Leica 
EC3 digital camera.  
 
2.16.7 Transfection of mammalian cell line 
A repulsive membrane acidolysis (RMA)-based transfection reagent, Metafectene™ Pro was 
used to transfect cells. This reagent works on the principle that a DNA-lipid complex forms 
and cationic liposomes come into contact with DNA. These complexes are then transported 
via endocytosis through the outer cell membrane. These newly-formed endosomes possess 
H+ pumps which allow the acidification of the endosome. An osmotic disruption is caused 
and the lipoplexes are released into the cytoplasm. These lipoplexes must then enter the 
nucleus in order to be incorporated into the cell and this is made possible by cell division.  
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The standard protocol was followed as per the manufacturer’s instructions. CHO cells were 
seeded in a 6-well plate. Once 70 % cell confluency was achieved, solutions A and B were 
prepared. Solution A was made up of 1.0 μg of DNA for transfection in 50 μl of Hams F12 
media. Solution B contained 6.0 μl of Metafectene™ Pro transfection reagent in 50 μl of 
Hams F-12. The two solutions were then combined and gently pipetted up and down. The 
mixture was then allowed to stand at room temperature for 15-20 minutes. After the 
incubation period, the mixture was added to the cells and mixed by gentle swirling. The cells 
were then incubated at 37 °C and 5 % CO2 overnight. The transfection mixture was removed 
and complete media was added to the wells. The cells were then incubated at 37 °C and 5 % 
CO2 until selection was performed.  
 
2.17 Cytotoxicity assays 
 
2.17.1 Measurement of apoptosis using APOPercentage
TM
 apoptosis assay by flow cytometry 
Upon reaching 80-90 % confluency in 24-well culture plates, cells were treated with various 
concentrations of functionalised gold nanoparticles for 24 hours. As a positive control, 14 M 
camptothecin (a known inducer of apoptosis) was used to treat cells for 24 hours. For the 
purposes of a negative control, cells were left untreated for 24 hours. Media containing dead, 
floating cells was transferred to centrifuge tubes. Subsequent to trypsination at 37 C with 5 
% CO2, cells were transferred to a 15 ml centrifuge tube and these were centrifuged at 800 x 
g for 3 minutes. A 1:160 dilution of APOPercentage
TM
 dye was prepared and the cell pellet 
was resuspended in 200 l of this dye.  
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The tubes were incubated at 37 C with 5 % CO2 for 30 minutes. After incubation, 1500 l of 
1 X PBS was added to each of the tubes and the tubes were centrifuged at 800 x g for 3 
minutes. The cell pellet was resuspended in 200 l of 1 X PBS and the cells were acquired 
and analysed on a FACScan
TM
 (Becton Dickson) instrument, with a 488 nm Argon laser as 
light source. This was done within one hour of the assay. Cells were acquired by setting the 
forward scatter (FSC) and side scatter (SSC) on a log scale dot plot. A linear histogram dot 
plot was used to measure APOPercentage
TM
 on the FL-3 channel, which was measured 
against relative cell number. A minimum of 10 000 cells per sample was acquired and 
analysed using CellQuest™ Pro software (Meyer et al., 2008). 
 
2.17.2 Measurement of cellular viability using 7-Aminoactinomycin D (7-AAD) nucleic acid 
dye 
Upon reaching 80-90 % confluency in 24-well culture plates, cells were treated with various 
concentrations of functionalised gold nanoparticles for 24 hours. As a positive control, 14 M 
camptothecin was used to treat cells for 24 hours. For the purposes of a negative control, cells 
were left untreated for 24 hours. Subsequent to incubation at 37 C with 5 % CO2, cells were 
transferred to a 15 ml centrifuge tube and centrifuged at 800 x g for 3 minutes. Cells were 
then resuspended in media containing 20 µg/ ml 7-AAD. Cells were then incubated at 4 C in 
the dark for 20 minutes. Cells were acquired and analysed on a FACScan
TM
 (Becton 
Dickson) instrument, with a 488 nm Argon laser as light source. Cells were acquired by 
setting the forward scatter (FSC) and side scatter (SSC) on a log scale dot plot. A linear 
histogram dot plot was used to measure 7-AAD uptake in FL-3, which was measured against 
relative cell number. A minimum of 10 000 cells per sample was acquired and analysed using 
CellQuest™ Pro software.  
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2.17.3 Measurement of cytotoxicity using the ApoTox-Glo™ Triplex Assay (Promega) 
Upon reaching 80-90 % confluency in 96-well culture plates, cells were treated with various 
concentrations of functionalised gold nanoparticles for 24 hours. As a positive control, 0.2 
µM camptothecin was used to treat cells for 24 hours. For the purposes of a negative control, 
cells were left untreated for 24 hours, so as to distinguish between normal and treated cells.  
After incubation at 37 C with 5 % CO2 for 24 hours, cells were treated with 20 µl of 
Viability/Cytotoxicity reagent, containing bis-AAF-R110 substrate, a fluorogenic cell-
impermeant peptide substrate to measure dead-cell protease activity. Only cells that have lost 
membrane integrity are capable of producing a fluorescent signal. After orbital shaking to 
evenly distribute the reagent on cells, the plates were incubated for a further 30 minutes at 37 
C. After incubation, the fluorescent signal from treated cells was measured at an excitation 
wavelength of 485 nm and an emission wavelength of 520 nm, using the POLARstar Omega 
plate reader from BMG Labtech. 
 
2.18 RNA Isolation from cells 
RNA was isolated from cells using Trizol® Reagent from GibcoBRL according to 
manufacturer’s instructions. In brief, Trizol Reagent was added to cells and lysis was 
carried out by passing the cells in Trizol Reagent through a pipette tip several times. The 
aqueous phase was separated from the phenol-chloroform phase by centrifugation at 12 000 x 
g. The aqueous phase was transferred to a fresh microcentrifuge tube and the RNA was 
precipitated by the addition of isopropyl alcohol. Samples were incubated at room 
termperature for 10 minutes and the RNA pellet was collected by centrifugation at 12 000 x g 
for 10 minutes at 4 °C. The supernatant was discarded and the RNA pellet was washed in 
75% ethanol. The pellet was again collected by centrifugation at 7 000 x g at 4 °C.  
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The RNA pellet was allowed to air-dry at room temperature before redissolving the pellet in 
RNase-free water. RNA was stored at -20 °C until used. 
 
2.19 cDNA synthesis from RNA 
cDNA was synthesised according to manufacturer’s instructions using the Improm-II® 
Reverse Transcription Kit from Promega. In brief, isolated RNA was combined with oligo 
(dT)15 primers and incubated at 70 C for 5 minutes. After chilling on ice for 5 minutes, 
reverse transcription mix was prepared, to which the RNA and oligos were added. Primers 
were annealed at 25 C for 5 minutes, followed by first-strand cDNA synthesis at 42 C for 
60 minutes. The reverse transcriptase was heat-inactivated at 70 C for 15 minutes and cDNA 
samples were stored at -20 C until further use. 
 
2.20 Western blot analysis 
Protein samples were electrophoresed on PAGE gels as described in Section 2.4. The proteins 
were transferred onto a PVDF-P membrane (GE Healthcare) using a Mini Protean IIsystem 
(Bio-Rad). Before transfer the membrane was pre-wet in methanol for a few seconds, washed 
in deionised water for 5 minutes and equilibrated in Transfer Buffer for 10 minutes. The SDS 
PAGE gels were also equilibrated in Transfer Buffer for 10 minutes. Transfer was performed 
at 4 °C, 100 V (constant voltage) for 1 hr in pre-cooled Transfer Buffer. After transfer the 
membranes were stained with Ponceau S (Sigma) to check for protein transfer. The 
membranes were incubated in TBS-MT for 1 hr.  
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The purified primary antibody was diluted (1:5 000 for His-probe, 1:500 for caspase-3 and 
1:1000 for V5 epitope) in TBS-MT and the membranes were incubated in the primary 
antibody overnight. The membrane was washed three times for 10 minutes in TBS-MT.  
The secondary antibody was diluted (1:20 000) in TBS-MT and the membranes were 
incubated in this antibody for 1 hour. The membrane was washed three times for 10 minutes 
in TBS-MT. This was followed by three more washes with TBS-T.  
Detection was performed using the SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific), which was added to the membrane. The membrane was exposed to the 
film in the dark at 1 minute and 5 minute intervals and then developed, using developer and 
fixer from Agfa Healthcare, and processed using the Curix 60 Film Processor from Agfa.  
 
2.21 Microscopy 
Cell morphology was monitored using a Nikon light microscope at 40 X magnification.  
Cells containing fluorescent constructs were visualised using the Zeiss Axioplan 2 
Fluorescence Microscope. For this process, cells were cultured on coverslips and then fixed 
in 4 % paraformaldehyde. Coverslips were mounted on a microscope slide using either 1 X 
PBS or Mowiol mounting medium. Images were taken at 40 X magnification using an 
Axiocam HRM microscope camera. 
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2.22 Gold nanoparticle preparation and synthesis 
Gold nanoparticles were synthesised by the citrate reduction method (Brust et al. 1994), by 
Dr Ndabenhle Sosibo at the Advanced Materials Division, Mintek SA. Various other gold 
nanoparticles were synthesised together with Mr Francois Taute in the Biotechnology 
Department at the University of the Western Cape. 
Gold nanoparticle synthesis can be done using various methods. The methods that were 
employed to produce the particles used in this study were the citrate reduction method as well 
as the one-pot dual-ligand functionalisation of nanoparticles (Zheng and Huang, 2007). The 
citrate reduction method involved the addition of 17 mM trisodium citrate to 0.3 mM gold 
chloride to produce gold nanoparticles at around 14 nm in size. This synthesis, as well as the 
subsequent functionalisation with nitriloacetic acid (NTA), was carried out by Dr Ndabenhle 
Sosibo at the Advanced Materials Division, Mintek SA. 
 
The one-pot method involved the addition of desired chemical functional groups, at pre-
determined concentrations of 0.25 mM each, to a 1 mM gold chloride solution, and the 
dropwise reduction of this mixture by 1 mM sodium borohydride in a single reaction while 
stirring. The mixture was allowed to stir for an hour after which particles were collected by 
centrifugation at 3500 x g. The particles were then resuspended and dialysed in 0.3 M MES 
buffer (pH 6.5) using the Slide-A-Lyzer Dialysis cassette G2 with a 7 kDA cut off size from 
Thermo Scientific. The resultant particles can vary in size, depending on the concentration of 
individual reagents added to the mixture. To facilitate optimal cellular uptake of the 
nanoparticles, the synthesised particles were synthesised to yield 14 nm sized particles.  
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2.22.1 Nickel titration of NTA-functionalised gold nanoparticles for the conjugation of 
Histidine-tagged proteins  
In order to conjugate His-tagged proteins to NTA- functionalised gold nanoparticles, a nickel 
titration was done to determine which concentration of nickel would result in the conjugation 
of the His-tagged proteins, and thus a shift in the surface plasmon resonance (SPR) band of 
the particles. This was done by adding the His-tagged proteins to NTA-functionalised 
nanoparticles, and titrating with various concentrations of nickel sulphate.  
The concentration that yielded the most dramatic shift in the SPR band of the particles, while 
maintaining the integrity of the nanoparticles, was 0.5 mM nickel sulphate (NiSO4).  
 
2.23 Gold nanoparticle characterisation 
Characterisation of gold nanoparticles is usually done by either UV-Vis spectroscopy or 
transmission electron microscopy (TEM) or both. For the purposes of the project, both 
methods were employed to characterise gold nanoparticles.  
 
2.23.1 UV-Vis spectroscopy 
UV-Vis spectroscopy was performed on nanoparticles using the POLARstar Omega plate 
reader from BMG Labtech. Spectra were collected in a range of 400-700 nm in 1 nm 
increments. Based on data by Haiss and colleagues in 2007, UV-Vis spectra data was used to 
extrapolate the size and concentration of synthesised gold nanoparticles using various 
extinction coefficients and the peak absorbance values of gold nanoparticles (Haiss et al., 
2007).  
 
 
 
 
84 
 
2.23.2 Transmission electron microscopy (TEM) 
High resolution transmission electron microscopy (HR-TEM) images were taken by Dr 
Subelia Botha using the HR-TEM instrument at the Physics Department of the University of 
the Western Cape. Transmission electron microscopy (TEM) of biological samples was 
performed by the National Health Laboratory Services (NHLS) at Tygerberg Hospital. The  
HR-TEM images served to verify the size and structure of nanoparticles, while the biological 
TEM demonstrated the size of nanoparticles as well as whether they were taken up by cells.  
 
2.23.3 Energy-dispersive X-ray spectroscopy (EDX) 
Energy-dispersive X-ray spectroscopy or EDX is an analytical technique used for the 
chemical characterisation of a sample based on the atomic structure of each element. These 
atomic structures result in the formation of unique peaks for each element on its X-ray 
spectrum. A high energy beam of charged electrons is used to excite the atoms in a sample, 
resulting in the formation of these unique peaks, allowing for the analysis of the elemental 
composition of a given sample. The HR-TEM data and EDX spectra were generated 
simultaneously by the same transmission electron microscope.  
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CHAPTER 3: CONSTRUCTION OF A “HIV-INFECTED” CELL  MODEL SYSTEM 
3.1 Introduction 
For the purposes of this study, the effect of a cell death inducing protein, caspase-3, on HIV-
infected cells was to be investigated to determine whether HIV-infected cells could be 
specifically targeted and destroyed. Given the nature of cells containing infectious material 
and the harm that it potentially poses, it is common practice in scientific disease research to 
generate a non-infectious, cell model system, which mimics the conditions of the disease 
under investigation. In this study, CHO cells were genetically engineered to mimic HIV 
infection by inducing expression of CD4 and HIV-1 protease. 
In order to make it possible for mammalian CHO cells to express the proteins mentioned 
previously, the individual genes were amplified, cloned into mammalian expression vectors 
(pEGFP-N3 and pcDNA
™
 3.1D/V5-His-TOPO), as described in section 2.10 Chapter 2 and 
transfected into CHO cells as described in section 2.16.7. Many methods for DNA 
transfection exist, but in this study, a polycationic transfection reagent based on liposome 
technology was used to introduce plasmid DNA into mammalian cells. Transfected cells were 
placed under selection pressure, resulting in the stable expression of CD4 and HIV-1 
protease. Since both pEGFP-N3 and pcDNA
™
 3.1D/V5-His-TOPO use the same antibiotic 
(G418) for the selection of stably transfected cells, cells were co-transfected with pEGFP-N3-
CD4 and pcDNA
™
 3.1D/V5-His-TOPO-HIV-1 protease at a concentration ratio 1:10, as 
demonstrated by Figure 3.1.  
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Figure 3.1 Schematic representation of mammalian cells co-transfected with CD4 and HIV-1 
protease. 
 
3.2 Cloning of CD4 into pEGFP-N3 
 
CD4 was PCR amplified from immortalised human T lymphocytes called Jurkat T cells. 
Since pEGFP-N3 allows for the expression of GFP tagged fusion proteins, cells expressing 
CD4-GFP can be visualised under a fluorescence microscope. Consequently, these cells can 
also be sorted by flow cytometry.  
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3.2.1 PCR amplification of CD4 
The human CD4 DNA sequence was PCR amplified from cDNA generated from Jurkat T 
cells. The CD4 Forward Primer and CD4 reverse primer A (listed in Table 2.2) was used to 
amplify CD4 as described in section 2.14.  
 
 
 
 
 
Figure 3.2 1% Agarose gel electrophoresis of PCR product of CD4. Lane 1 indicates a molecular 
weight marker. Lanes 2-4 indicate PCR amplified CD4. Lane 5 indicates the negative control for the 
PCR containing nuclease-free water. 
 
After amplification by PCR (seen in Figure 3.2) the samples were electrophoresed on an 
agarose gel, as described in section 2.3. Upon detection of DNA (section 2.3.3) a band 
corresponding to the expected size for the CD4 gene could be observed at ~1.2 kb. Suspected 
CD4 PCR products were excised and purified from a 1 % agarose gel, as described in section 
2.3.4. The purified DNA was used as an insert to clone into the pEGFP-N3 plasmid vector. 
EcoRI and XmaI restriction sites were engineered into the CD4 Forward Primer and CD4 
reverse primer A, respectively. After gel purification, the purified PCR product was digested 
with EcoRI and XmaI restriction enzymes as described in section 2.11. 
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3.2.2 Preparation of pEGFP-N3 for cloning 
 
Large-scale preparation of pEGFP-N3 plasmid DNA was performed by CsCl/EtBr 
fractionation, as described in section 2.7. As indicated in Figure 3.3, the plasmid DNA was 
cut with EcoRI and XmaI restriction enzymes, as described in section 2.11 and purified from 
an agarose gel (section 2.3.4) to prepare the plasmid vector for ligation of the CD4 insert.  
 
 
 
 
 
 
Figure 3.3 1% Agarose gel electrophoresis of restriction enzyme digested pEGFP-N3 plasmid DNA. 
Lane 1 indicates a molecular weight marker. Lane 2 indicates undigested pEGFP-N3 plasmid DNA. 
Lane 3 indicates pEGFP-N3 cut with EcoRI and Lane 4 indicates pEGFP-N3 cut with XmaI.  
 
As seen in Figure 3.3, circular pEGFP-N3 plasmid DNA was digested with restriction 
enzymes to produce linearised DNA with the overhangs needed for ligation of EcoRI and 
XmaI digested the CD4 PCR product.  
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3.2.3 Ligation of CD4 into pEGFP-N3 
Once the CD4 PCR product and pEGFP-N3 plasmid were both digested with restriction 
enzymes and purified, a ligation reaction was performed to ligate the sticky ends of CD4 
insert into the mammalian expression vector, pEGFP-N3, as described in section 2.12. 
Ligation reactions were used to transform into E.coli MC1061 cells, as described in section 
2.13.4. The resulting clones were screened by colony PCR (as described in section 2.14.2) for 
the presence of pEGFP-N3-CD4. Figure 3.4 shows the results of the colony PCR on 6 clones. 
Distinct bands can be observed at the expected size for the CD4 gene (~1.2 kb). A number of 
non-specific products of higher molecular weight can also be observed.  
Plasmid DNA was prepared from 3 of these clones, as described in section 2.6, and samples 
were sent to Inqaba Biotechnical Industries (Pty) Ltd for sequence analysis.  
 
 
 
 
Figure 3.4 1% Agarose gel of colony PCR screen for CD4 cloned into pEGFP-N3. Lane 1 indicates 
molecular weight marker. Lanes 2-7 indicate colonies 1-6 for CD4 cloned into pEGFP-N3. Lane 8 
indicates the negative control for the PCR containing nuclease-free water. 
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3.2.4 Sequence analysis of pEGFP-N3-CD4 
Plasmid DNA from 3 positive clones (colony 3, 4 and 5) (see section 3.2.3) was sent to 
Inqaba Biotechnical Industries (Pty) Ltd for sequence analysis. The Basic Local Alignment 
Search Tool (BLAST
®
) from the National Centre for Biotechnology Information (NCBI) was 
used to perform an amino acid sequence alignment of human CD4 sequence (accession 
number, NM_000616) with pEGFP-N3-CD4. Upon analysis of the data, there was a 99 % 
amino acid sequence match between human CD4 from the database and pEGFP-N3-CD4 
clone 5, as demonstrated by Figure 3.5.  
This clone demonstrated the highest sequence similarity to human CD4 and was selected for 
mammalian transfection of pEGFP-N3-CD4 into CHO cells. 
 
 
 
CD4         IVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKN  
199-258     |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
EGFP-N3-CD4 IVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKN  
1-60 
 
CD4         KEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMR         
259-318     ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| 
EGFP-N3-CD4 KEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLTLTLEAKTGKLHQEVNLVVMR   
61-120 
 
CD4         ATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQV  
319-378     |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
EGFP-N3-CD4 ATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQV  
121-180 
 
CD4         LLESNIKVLPTWSTPV   
379-394     |||||||||||||||| 
EGFP-N3-CD4 LLESNIKVLPTWSTPV   
181-196 
 
 
Figure 3.5 Amino acid sequence alignment of the Homo Sapiens CD4 (NM_000616) and pEGFP-
N3-CD4 clone 5. 
 
 
 
 
 
92 
 
3.3 Cloning of HIV-1 protease into pcDNA
™
 3.1D/V5-His-TOPO 
The pBAD-TOPO-HIV-1 protease plasmid was obtained from Ms Zarinah Sonday at the 
Institute for Infectious Diseases and Molecular Medicine (IIDMM) at the University of Cape 
Town. Two primers, HIV-1 protease TOPO Forward and Reverse, were designed to PCR 
amplify and clone HIV-1 protease from the aforementioned vector into pcDNA™3.1D/V5-
His-TOPO (Invitrogen™) (see Table 2.2). 
 
3.3.1 PCR amplification of HIV-1 protease 
 
HIV-1 protease was PCR amplified from pBAD-TOPO-HIV-1 protease using primers that 
would facilitate the directional cloning of HIV-1 protease into pcDNA™3.1D/V5-His-TOPO 
mammalian expression vector. PCR amplification was performed as described in section 
2.14. 
 
 
 
 
Figure 3.6. 1% Agarose gel electrophoresis of HIV-1 protease PCR. Lane 1 indicates the molecular 
weight marker. Lane 2 indicates the negative control of the PCR containing nuclease-free water. Lane 
3 indicates PCR amplified HIV-1 protease.  
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A 300 bp product was generated, as indicated in Figure 3.6, corresponding to the expected 
size of HIV-1 protease. The PCR product was isolated from the agarose gel, purified (as 
described in section 2.3.4) and used as an insert to clone into the pcDNA™3.1D/V5-His-
TOPO expression vector. 
 
3.3.2 Ligation of HIV-1 protease into pcDNA
™
 3.1D/V5-His-TOPO 
The gel purified DNA was ligated into pcDNA
™ 
3.1 1D/V5-His-TOPO, as described in 
section 2.12. The cloning was performed using the Directional TOPO
®
 Expression Kit 
(Invitrogen™). The ligated DNA was transformed into E.coli cells, as described in section 
2.13.4. After plating transformations on agar plates containing the appropriate antibiotic, the 
resulting colonies were selected and screened for the presence of HIV-1 protease by colony 
PCR (as described in section 2.14.2), as indicated by Figure 3.7.  
 
 
 
 
 
Figure 3.7 1% Agarose gel of colony PCR products to screen for HIV-1 protease cloned into 
pcDNA
™ 
3.1 1D/V5-His-TOPO. Lane 1 indicates a molecular weight marker. Lanes 2-11 indicate 
colonies 1-10 for HIV-1 protease cloned into pcDNA
™ 
3.1 1D/V5-His-TOPO. Lane 12 indicates 
the negative control for the PCR containing nuclease-free water. 
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As demonstrated by Figure 3.7, a PCR product which corresponds to the expected size of 300 
bp for HIV-1 protease was generated. A 300 bp band is also visible in the negative control, 
possibly indicating seeping from lane 11 into the negative control lane, but the intensity of 
the band is much lower in comparison to the experimental samples that were screened. Five 
of the clones were selected, plasmid DNA was prepared (as described in section 2.6) and 
samples were sent to Inqaba Biotechnical Industries (Pty) Ltd to be sequenced.  
 
3.3.3 Sequence analysis of pcDNA
™
 3.1D/V5-His-TOPO-HIV-1 protease 
Plasmid DNA from 5 positive clones (colony 1, 2, 3, 4 and 5) (see section 3.2.3) was sent to 
Inqaba Biotechnical Industries (Pty) Ltd for sequence analysis. The Basic Local Alignment 
Search Tool (BLAST
®
) from the National Centre for Biotechnology Information (NCBI) was 
used to perform an amino acid sequence alignment of HIV-1 protease in the sequence 
database with pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease. Upon analysis of the data, 
there was a 100 % amino acid sequence match between HIV-1 protease from the database 
and pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease clone 5, as demonstrated by Figure 3.8. 
This clone demonstrated the highest sequence similarity to HIV-1 protease and was selected 
for mammalian transfection of pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease into CHO 
cells. 
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Synthetic  MPQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQY   
1-60       |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Clone 5    MPQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQY   
1-60 
Synthetic  DQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTL   
61-98      |||||||||||||||||||||||||||||||||||||| 
Clone 5    DQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTL   
61-98 
 
 
Figure 3.8 Amino acid sequence alignment of a synthetic HIV-1 protease, labelled “Synthetic” with 
pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease clone 5, labelled “Clone 5”. 
 
3.4 Transfection of pEGFP-N3-CD4 and pcDNA
™
 3.1D/V5-His-TOPO-HIV-1 protease 
into CHO cells 
Plasmid DNA was prepared for pEGFP-N3-CD4 and pcDNA™ 3.1D/V5-His-TOPO-HIV-1 
protease, as described in section 2.6. CHO cells were cultured in 6-well plates and co-
transfected with the plasmids, as described in section 2.16.7. Transfection was achieved using 
Metafectene™ Pro transfection reagent from Biontex. To produce stable transfectants, 
selection pressure was applied. Since both vectors make use of neomycin as a selectable 
marker, G-418 solution from Roche was used to select positive transfectants at a 
concentration of 800µg/ml. Figure 3.9 A) shows that un-transfected cells are killed by G-418 
treatment, while Figure 3.9 B) shows co-transfected with pEGFP-N3-CD4 and pcDNA™ 
3.1D/V5-His-TOPO-HIV-1 protease plasmid DNA are resistant to G418. 
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Figure 3.9 Light microscopy images of CHO cells co-transfected with pEGFP-N3-CD4 and 
pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease. A) Untransfected CHO cells 7 days after selection. 
B) CHO cells co-transfected with pEGFP-N3-CD4 and pcDNA™ 3.1D/V5-His-TOPO-HIV-1 
protease 7 days after selection. Images were captured at a 20X magnification. 
 
3.5 Evaluation of pEGFP-N3-CD4 expression in CHO cells 
After CHO cells were successfully transfected with GFP-N3-CD4 and pcDNA™ 3.1D/V5-
His-TOPO-HIV-1 protease, cells were cultured on cover slips. The cells were prepared for 
microscopy by fixing the coverslips in 4 % paraformaldehyde, as described in section 2.21. 
After fixation, cover slips were mounted onto microscope slides, using Fluoroshield™ with 
DAPI (4',6-diamidino-2-phenylindole). DAPI is a fluorescent stain that binds to AT regions 
of DNA sequences and used in fluorescence microscopy to stain cell nuclei. Since CD4 will 
be expressed as a fusion protein with GFP, and the sequence data shows no mutations or stop 
codons between GFP and CD4, the presence of GFP can be used as an indication of the 
presence of CD4. Moreover, since the concentration of the pcDNA™ 3.1D/V5-His-TOPO-
HIV-1 protease was 10 times greater than that of pEGFP-N3-CD4, the presence of pEGFP-
N3-CD4 would indicate that both plasmids were successfully transfected. CHO cells co-
transfected with pEGFP-N3-CD4 and pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease were 
visualised using the Zeiss Axioplan 2 Fluorescence Microscope. Images were taken using the 
Axiocam HRM microscope camera.  
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Figure 3.10 Fluorescence microscopy images of CHO cells co-transfected with pEGFP-N3-CD4 and 
pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease. A) Transfected CHO cells captured using the blue 
fluorescence filter of the microscope. B) Transfected CHO cells captured using the green fluorescence 
filter of the microscope. C) An overlay of images A) and B). 
 
Figure 3.10 A) shows that 100% of the cells stain blue with DAPI, while Figure 3.10 B) 
shows that ~70 % of the cells are positively expressing GFP. The fluorescence of DAPI 
staining is localised to the nucleus while the fluorescence of GFP is dispersed all over the 
cell. In order to achieve a homogenous cell population where all the cells express GFP, the 
cells were sorted by Fluorescence Activated Cell Sorting (FACS).  
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3.5.1 Sorting transfected CHO cells towards establishing a homogenous 
population of transfected cells 
FACS was performed on CHO cells co-transfected with pEGFP-N3-CD4 and pcDNA™ 
3.1D/V5-His-TOPO-HIV-1 protease. This process was used to generate a homogenous 
population of cells co-transfected with pEGFP-N3-CD4 and pcDNA™ 3.1D/V5-His-TOPO-
HIV-1 protease. Cells co-transfected with pEGFP-N3-CD4 and pcDNA™ 3.1D/V5-His-
TOPO-HIV-1 protease will fluoresce green. Sterile cell sorting was performed using the BD 
FACSVantage SE flow cytometer. All cell-sorting experiments were performed by Mr 
Ronnie Dreyer at the Department of Immunology at the University of Cape Town. The mixed 
(transfected and un-transfected) population of CHO cells was trypsinised, as described in 
section 2.16.4, and then placed in the flow cytometer for sorting transfected cells from un-
transfected cells. GFP-expressing cells were detected in the FL1 channel of the flow 
cytometer. This sorting process ensured that a pure population of transfected CHO cells was 
obtained. As a negative control un-transfected CHO cells was used as a reference sample to 
distinguish between transfected (green fluorescing) and un-transfected (non-fluorescing) 
cells.  
The histograms in Figure 3.11 show the relative fluorescence of the cells. Figure 3.11-A 
shows a single peak for un-transfected, non-fluorescing control cells between 10
0
 and 10
1
 on 
the x-axis, which is in the M1 region of the histogram. Figure 3.11-B shows two distinct 
peaks. One peak between 10
0
 and 10
1
,
 
and a second between 10
1
 and 10
3
. The cells in the 
second peak (also indicated in the M2 region of the histogram) make up ~90% of the total 
cell population, fluorescing green and respresenting the co-transfected cells. The cells were 
subjected to FACS to sort out the green fluorescing cell. Figure 3.11-C shows fluorescence in 
these cells after cell sorting was performed.  
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Figure 3.11-C shows that close to 99% of the cells are in the second peak. These cells were 
transferred to cell culture flasks and cultured as usual, according to standard cell culture 
protocols.  
 
 
 
 
  A)     B)     C)  
Figure 3.11 Fluorescent activated cell sorting of CHO cells co-transfected with pEGFP-N3-CD4 and 
pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease. A) GFP fluorescence in un-tranfected CHO cells B) 
GFP fluorescence in tranfected CHO cells before sorting by flow cytometry C) GFP fluorescence in 
tranfected CHO cells after sorting flow cytometry. 
 
3.6 Summary 
CD4 and HIV-1 protease PCR products were successfully cloned into mammalian expression 
vectors, as confirmed by DNA sequence data. The sequenced constructs, pEGFP-N3-CD4 
and pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease, were then co-transfected into CHO cells 
to generate a cell line expressing both CD4 as well as HIV-1 protease. The presence of CD4 
in these cells was confirmed by fluorescence microscopy as well as flow cytometry. In view 
of the above-mentioned data, a cell line representing HIV infected cells was successfully 
generated by gene engineering. These “HIV-infected cells” were used to target a HIV-1 
protease-cleavable mutant caspase-3 nanostructure, with the expectancy that the targeted 
nanostructure would induce programmed cell death in the “HIV-infected cells”.  
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CHAPTER 4. GENERATION OF MUTANT CASPASE-3 IN A BACTERIAL 
EXPRESSION SYSTEM FOR TARGETING TO “HIV-INFECTED” CELLS 
 
4.1 Introduction 
Apoptosis, or programmed cell death, is a biological process that is characterised by the 
controlled destruction of cells, accompanied by distinct morphological changes that occur in 
these cells. Caspase-3 is an executioner caspase that cleaves cellular proteins, giving rise to 
the morphological changes characteristic of apoptosis (Wyllie 2010). Vocero-Akbani and 
colleagues demonstrated that a mutant form of caspase-3 that was activated by HIV-1 
protease is able to kill HIV-infected cells through the activation of apoptosis (Vocero-Akbani 
et al., 1999).  
The aim of this study, is to achieve more specific, targeted destruction of HIV-infected cells. 
In the presence of an HIV-infected cell expressing HIV-1 protease, the mutant caspase-3 is 
activated, resulting in controlled, programmed cell death also known as apoptosis. A mutant 
caspase-3 was designed by introducing cleavage sites A (SQVSQNY-PIVQNLQ) and D 
(CTERQAN-FLGKIWP) for HIV-1 protease into the sequence of wildtype caspase-3. 
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 4.2 Design and synthesis of mutant caspase-3  
The DNA synthesis for mutant caspase-3 was based on the DNA sequence of caspase-3. The 
sequence was designed to contain an N-terminal polyhistidine tag, followed by the mutant 
caspase-3 containing the HIV-1 protease sites, A and D. Figure 4.1 A) shows the N-terminal 
polyhistidine tag followed by HIV-1 protease cleavage site D. This is flanked by the p17 
subunit of caspase-3. Thereafter the second cleavage site for HIV-1 protease, A, is shown and 
is flanked by the p12 subunit of caspase-3. A simplified version of the synthesised contruct is 
demonstrated by Figure 4.1 B). 
 
 
 
 
 
 
 
 
Figure 4.1 A) Mutant caspase-3 amino acid sequence for cloning into pET21b bacterial expression 
vector.   
 
 
 
 
 
 
 
 
103 
 
 
 
 
 
 
 
B) Animated version of mutant caspase-3 design for cloning into pET21b bacterial expression vector.   
 
The DNA sequence information was sent to GenScript for optimised gene synthesis and 
subcloning into the pET21b bacterial expression vector, thereby generating pET21b-mutant 
caspase-3. 
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4.3 Expression and purification of mutant caspase-3 
To determine expression of mutant caspase-3, the construct obtained from GenScript, as 
described in section 4.2, was transformed into E.coli BL21 codon plus™ cells, as described 
in section 2.13.4. Cells were plated on luria agar containing 100 µg/ ml ampicillin. After 
incubating plates at 37° C overnight, 4 colonies were selected and these were screened for 
expression of mutant caspase-3 by inducing cultures with IPTG, as described in section 
2.14.1. Figure 4.2 shows the expression levels of mutant caspase-3 in E.coli. 
 
 
 
 
 
Figure 4.2 12% SDS-PAGE gel demonstrating expression of mutant caspase-3 in E.coli. E.coli BL21 
codon plus™ colonies transformed with pET21b-mutant caspase-3 were screened to determine 
expression of the His-tagged fusion protein. Lane 1 indicates a molecular weight marker. Lanes 2, 4, 6 
and 8 indicate uninduced protein samples, containing no IPTG. Lanes 3, 5, 7 and 9 indicate protein 
samples induced with 1 mM IPTG. A band corresponding to ~33 kDa relative to the protein marker is 
highly expressed. 
 
As can be seen from Figure 4.2, no demonstrable difference could be seen between clones 1-
4. Notably, the construct was equally well expressed in the uninduced samples as a result of 
leaky or unintended expression. Clone 4 was randomly selected and, a large-scale culture of 
pET21b-mutant caspase-3 was prepared and induced with IPTG, as described in section 
2.14.2.  
 
 
 
 
105 
 
The cell lysate was then purified on a nickel sepharose column, as described in section 
2.14.3. Fractions and elutes were collected by gravity for analysis by SDS-PAGE, as 
demonstrated by Figure 4.3. 
 
 
 
 
 
Figure 4.3 12% SDS-PAGE gel demonstrating nickel affinity purification of His-tagged mutant 
caspase-3 from E.coli. Lane 1 indicates a molecular weight marker. Lane 2 indicates the bacterial 
lysate subsequent to induction, while lane 3 indicates the flow-through after the lysate was passed 
over the nickel affinity column. Lanes 4-6 indicate the wash fractions containing 40 mM imidazole. 
Lanes 7-9 indicate purified protein fractions after elution with 250 mM imidazole.  
 
As indicated by Figure 4.3, a ~33 kDa protein was eluted from the nickel affinity column, 
corresponding to the expected size of the mutant caspase-3 protein. The eluted protein from 
lanes 7-9 were pooled and stored at -20° C. To confirm that the 33 kDA protein was indeed 
mutant caspase-3, purified samples were loaded on an SDS-PAGE gel and Western blot 
analysis was done using a caspase-3 antibody.  
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Figure 4.4 A) 12% SDS-PAGE gel of purified mutant caspase-3. Lane 1 indicates a molecular weight 
marker. Lanes 2-4 indicate purified samples of the 33 kDa protein. B) Western blot analysis of 
purified mutant caspase-3, probed with a caspase-3-specific antibody . Lanes 1-3 indicate the purified 
protein samples shown in A, probed with caspase-3 antibody. 
 
Figure 4.4 A) shows the eluted 33 kDa protein electrophoresed on an SDS-PAGE gel, as 
described in section 2.4. Figure 4.4 B) is a Western blot that was performed on the eluted 
samples. The Western blot confirmed that the 33 kDa protein was indeed a caspase-related 
protein, and was likely to therefore be the mutant caspase-3. Once expression and purification 
of mutant caspase-3 was confirmed by Western blot, as demonstrated by Figure 4.4, purified 
protein was dialysed in MES buffer using a Slide-A-Lyzer Dialysis Cassette from Thermo 
Scientific, with a molecular weight cut off of 7 kDa. The protein was lyophilised and stored 
at -80° C, as described in section 2.15.4. 
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4.4 Summary  
The aim of the study was to generate a mutant form of the apoptosis-inducing protein, 
caspase-3, that is cleavable only by HIV-1 protease. Mutant caspase-3 was designed and 
synthesised, and the histidine-tagged construct was successfully expressed and purified. The 
results demonstrated here show the successful generation of a mutant form of caspase-3, to be 
used as a pro-apoptotic agent for the induction of apoptosis in “HIV-infected” cells. The 
generation of a cell line representing HIV infection was previously demonstrated (Chapter 3) 
and serves as the target for the death-inducing agent, mutant caspase-3. The expected 
outcome, therefore, is that the HIV-1 protease believed to be expressed by the cell line will 
result in the mutant caspase-3 becoming active, thereby eliciting apoptosis in those cells. 
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CHAPTER 5. DESTRUCTION OF “HIV-INFECTED” CELLS USING CD4-
TARGETING Ni-NTA MUTANT CASPASE-3 GOLD NANOPARTICLES  
 5.1 Introduction 
5.2 Toxicity testing of gold nanoparticles prior to functionalisation with a CD4-
targeting peptide and mutant caspase-3  
5.3 Synthesis and characterisation of gold nanoparticles 
5.4 Cell viability and apoptosis induction of “HIV-infected” cells treated with 
NTA-gold nanoparticles functionalised with a CD4-targeting peptide and mutant 
caspase-3 
5.6 Summary  
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CHAPTER 5. DESTRUCTION OF “HIV-INFECTED” CELLS USING CD4-
TARGETING Ni-NTA MUTANT CASPASE-3 GOLD NANOPARTICLES  
5.1 Introduction 
Gold nanoparticles possess a wide variety of applications in the field of biotechnology. These 
applications include disease detection, cellular imaging as well as sensor technology. Due to 
their inert nature and small size, gold nanoparticles have also been investigated for the 
purposes of targeted drug delivery in cellular systems. Gold nanoparticles have been shown 
to be particularly less toxic than other nanostructures and have therefore been identified as 
one of the nanostructures of choice in the field of drug delivery (Sperling et al., 2008). 
Another useful characteristic of gold nanoparticles is that these particles can be conjugated to 
biomolecules (Mishra et al., 2009). It is this ability to conjugate gold nanoparticles to 
biomolecules that prompted its use for the targeted delivery of the mutant caspase-3 that was 
generated, as described in Chapter 4.  
As described in Chapter 3, a mammalian cell line was generated that express HIV-1 protease 
as well as the CD4 receptor in an attempt to generate a model cell line that represents a HIV-
infected cell. To deliver mutant caspase-3 to these cells for the induction of apoptosis, gold 
nanoparticles would need to be targeted to them in some way. To this end, gold nanoparticles 
were synthesised and dual-functionalised with a CD4-targeting peptide as well as mutant 
caspase-3. 
In this study the gold nanoparticles were used to deliver mutant caspase-3 to cells. To 
demonstrate that the nanoparticles themselves are not toxic the toxcity of these particles were 
invesitigated. Mammalian cells were exposed to the nanoparticles and the toxicity of the 
particles were evaluated using 7-AAD staining and the APOPercentage™ assay .  
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5.2 Toxicity screening of gold nanoparticles prior to functionalisation with CD4-
targeting peptide and mutant caspase-3  
 
 
 
 
Figure 5.1. TEM images of gold nanoparticles conjugated with 50 % NTA NPs. 
 
Gold nanoparticles were synthesised and conjugated with nitriloacetic acid (NTA), as 
described in section 2.22. The TEM image in Figure 5.1 shows the sizes of synthesised and 
functionalised nanoparticles before cellular treatment. Once characterised by TEM, these 
particles were used to treat Jurkat T cells for 24 hours to determine the cytotoxic effect of 
these functionalised nanoparticles. As described in section 2.17.2, CHO cells were grown to 
~80 % visual confluency and treated with 2.5 x 10
11
 nanoparticles per well in a 24-well 
culture plate. Camptothecin was used as a positive control at a concentration of 0.2 µM (a 
concentration known to induce apoptotic cell death in CHO cells), while untreated cells 
served as the negative control. After incubating for 24 hours, cells were exposed to 20 µg/ml 
of 7-AAD staining solution.  
Viable and non-viable cells can be distinguished with 7-AAD, since this dye binds to double-
stranded DNA. The dye is not cell permeable and can therefore only stain the DNA in cells 
with damaged membranes. Non-viable cells were detected and counted by flow cytometry in 
the FL-3 channel.  
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Figure 5.2. Percentage of 7-AAD staining measured in CHO cells treated with functionalised gold 
nanoparticles. 50% NTA NPs represent nanoparticles functionalised with a 50 % ratio of nitriloacetic 
acid (NTA). 100 % OH NPs represent nanoparticles functionalised with 100 % hydroxyl functional 
group. Cells were treated with 2.5 X 10
11
 nanoparticles. 0.2µM camptothecin served as a positive 
control, while untreated CHO cells served as the negative control. 
 
As demonstrated by the graph in Figure 5.2, approximately 12 % of the untreated cells were 
non-viable. In the positive control (cells treated with camptothecin) nearly 60 % of the cells 
were non-viable. To further test that these gold nanoparticles, once functionalised with NTA, 
did not induce a cytotoxic response, CHO cells were treated with NTA-functionalised gold 
nanoparticles at various concentrations and apoptosis was measured by the APOPercentage™ 
assay, as described in section 2.17.3. Since CHO cells were used to generate the mammalian 
cell line representing HIV-infection, it was necessary to evaluate the toxicity of the NTA 
functionalised particles on these cells as well. CHO cells were grown to near visual 
confluency and treated in triplicate with three different concentrations of gold nanoparticles 
functionalised with NTA. From the data, represented by Figure 5.3, the negative control, 
containing untreated cells, showed less than15 % of the cells were positive for apoptosis. As 
for the positive control (cells treated with 0.2 µM camptothecin), more than 90 % of the cells 
were positive for apoptosis. Even at the maximum concentration of 0.5 nM, the NTA-
functionalised nanoparticles did not induce significant levels of apoptosis (less than 10 % 
apoptosis was observed).  
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Figure 5.3. Measurement of percentage apoptosis in CHO cells treated with increasing concentrations 
of NTA-functionalised gold nanoparticles.   
 
This demonstrates that at these concentrations, the particles did not result in cytotoxicity. 
Based on this data, and the fact that histidine-tagged proteins could be conjugated to NTA-
functionalised nanoparticles with greater ease and stability than other chemical interactions, 
these particles were selected for the assembly of a CD4-targeting, mutant caspase-3 gold 
nanoparticle. 
 
5.3 Characterisation of NTA-functionalised gold nanoparticles 
As mentioned in section 2.22, gold nanoparticles were synthesised by both citrate reduction 
as well as the one-pot dual-ligand functionalisation of gold nanoparticles.  
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Figure 5.4. Gold nanoparticles synthesised by the one-pot method (A) and the citrate method (B).  
 
As demonstrated by Figure 5.4 A and B, gold nanoparticles can vary in colour intensity, 
depending on the concentration of gold present in the sample. Citrate reduced nanoparticles 
were synthesised and then functionalised with NTA by Dr Sosibo Ndabenhle (Mintek), 
whereas with the one-pot method nanoparticles were functionalised with NTA during the 
synthesis process in a single step. Figure 5.5 demonstrates UV-Vis spectra of citrate reduced 
nanoparticles, as well as NTA-functionalised gold nanoparticles synthesised by the one-pot 
method. As the spectra suggest, the characteristic surface plasmon resonance (SPR) of 
unfunctionalised gold nanoparticles peaks at ~520 nm, while gold nanoparticles 
functionalised with NTA demonstrated a SPR maximum at ~530 nm. This clear shift in the 
SPR of the nanoparticles is only seen when nanoparticles are conjugated with a functional 
group.   
 
 
 
 
 
 
 
 
114 
 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
300 350 400 450 500 550 600 650 700 
A
b
so
rb
an
ce
 v
al
u
e
s 
Wavelength in nm 
Citrate-reduced  
NTA-capped 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. UV-Vis spectra of gold nanoparticles before and after functionalisation with NTA.   
 
 
 
 
 
Figure 5.6. Characterising NTA-functionalised gold nanoparticles synthesised by the one-pot dual-
ligand functionalisation method. A shows the HR-TEM analysis and B shows the EDX analysis. 
 
 
 
 
 
115 
 
The HR-TEM image of the gold nanoparticles functionalised with NTA (Figure 5.6 A) shows 
spherical particles with a diameter of 15-20nm. The particles appear relatively uniform in size 
and shape. The EDX data (Figure 5.6 B) shows the elemental composition of the 
nanoparticles. Various peaks are seen, each representative of the elements present in the 
sample. The nitrogen from the NTA is detected, as indicated by the N symbol. The gold from 
the gold nanoparticles is also detected, indicated by the Au symbol. The Cu indicates copper 
from the sample grid used to prepare the particles for TEM. The elemental composition 
depicted in Figure 5.6 B) further confirmed that NTA was indeed conjugated to the gold 
nanoparticles. These NTA-functionalised gold nanoparticles were stored at 4 °C until needed 
for further functionalisation.  
 
5.4 Cell viability of “HIV-infected” cells treated with NTA-gold nanoparticles 
functionalised with CD4-targeting peptide and mutant caspase-3 
The NTA-functionalised nanoparticles synthesised as described in section 2.22, by the one-
pot dual-ligand functionalisation method, were used as the base particles for conjugation of a 
His-tagged CD4-targeting peptide and a His-tagged mutant caspase-3. The His-tagged CD4-
targeting peptide was purchased from Thermo Scientific, while the His-tagged mutant 
caspase-3 was expressed and purified, as described in Chapter 4. The immobilisation of His-
tagged proteins onto NTA-functionalised gold nanoparticles was performed as described by 
Abad and colleagues. In this study, they conjugated His-tagged proteins onto NTA-
functionalised gold nanoparticles by 1-ethyl-3-[3´-(dimethylamino)propyl]carbodiimide 
(EDC)/ N-hydroxysuccinimide (NHS) chemistry (Abad et al., 2005).  
In this study, however, NTA was conjugated to gold nanoparticles in a single step during the 
synthesis process. His-tagged proteins were then added to NTA-functionalised gold 
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nanoparticles at a concentration ratio of 50:50 by adding NiSO4 to the reaction, as described 
in section 2.22.1. Three dilutions of NiSO4 were tested for conjugation in order to determine 
which concentration of NiSO4 would generate the best shift in SPR from baseline, and 
therefore indicate a more stable conjugation reaction between the NTA-functionalised 
nanoparticles and the 2 histidine-tagged proteins. As demonstrated by Figure 5.7, the greatest 
shift in the SPR of the particles resulted when a concentration of 0.5 mM NiSO4 was added to 
the reaction, indicated by the red curve. When compared to the control, which contained only 
NTA-functionalised gold nanoparticles, the addition of 0.5 mM NiSO4 to particles containing 
the histidine-tagged proteins indicated a distinct shift in the SPR maxima of the particles, 
indicating the stable conjugation of protein onto the surface of Au-NTA particles. 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. UV-Vis spectra of NTA-gold nanoparticles functionalised with CD4-targeting peptide and 
mutant caspase-3. 
 
After determination of a concentration of NiSO4 that would result in successful conjugation 
of histidine-tagged proteins onto Au-NTA nanoparticles, the dual-ligand conjugated gold 
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nanoparticles could be tested on cells. The “HIV-infected” cell model (described in Chapter 
3) was used to test the targeted delivery of these particles to these cells.  
As described in section 2.17.3, CHO cells representing HIV-infection were grown in 96-well 
plates until near visual confluency, and treated with increasing concentrations of 
functionalised gold nanoparticles for 24 hours. After treatment, 20 µl of viability/cytotoxicity 
reagent was added to cells and the plate was mixed briefly by orbital shaking.  
The reagent was incubated at 37 °C for 30 minutes before measuring fluorescence. The two 
substrates present in the reagent, namely the GF-AFC substrate and the bis-AAF-R110 
substrate, when cleaved, produce a fluorescent signal for viability and cytotoxicity 
respectively. The substrates each have their own excitation and emission wavelengths, 
making it possible to distinguish between a fluorescence signal for viability and for 
cytotoxicity. According to the protocol, cytotoxicity was measured at the excitation 
wavelength of 485 nm and an emission wavelength of 520 nm. Figure 5.8 demonstrates 
fluorescence (at the above-mentioned wavelengths) detected in cells treated with various 
concentrations of functionalised gold nanoparticles. The lowest concentration of particles, at 
125 pM has a low level of fluorescence, indicating decreased cytotoxicity in these cells. As 
the concentration of nanoparticles increases, there appears to be an increase in the amount of 
fluorescence detected, indicating increased cytotoxicity. The 500 pM concentration of 
particles seemed to produce a fluorescence signal of half the cytotoxicity of the most 
cytotoxic concentration of particles. This concentration was therefore selected as the 
concentration that would be toxic in half the population of cells over the 24 hour period 
(LC50).  
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Figure 5.8. Viability of CHO cells representing HIV-infection after 24 hour treatment with increasing 
concentrations of NTA-CD4-targeting peptide-mutant caspase-3 functionalised gold nanoparticles. 
Once the LC50 was determined to be 500 pM, as indicated by Figure 5.8, cells representing 
HIV infection were treated with this concentration of NTA-CD4-targeting peptide-Mutant 
caspase-3 gold nanoparticles for a period of 6 hours. Transfected cells expressing both CD4 
and HIV-1 protease were seeded at a cell number of 1 x 10
5
 cells per ml in a 6-well plate. As 
a negative control, one well, well A, containing only cells, was left untreated. The positive 
control, well B, contained cells treated with 50 % ethanol to demonstrate apoptosis-mediated 
cell death. Well C contained cells plus 500 pM NTA-gold nanoparticles. Well D contained 
cells plus 500 pM NTA-gold nanoparticles functionalised with CD4-targeting peptide. Well E 
contained cells plus 500 pM NTA-gold nanoparticles functionalised with mutant caspase-3. 
Finally, well F contained 500 pM NTA-CD4-targeting peptide-mutant caspase-3 gold 
nanoparticles. As a control experiment, untransfected CHO cells were also seeded at 1 x 10
5
 
cells per ml in a 6-well plate and treated identical to the transfected CHO cells, as described 
earlier. This experiment was done to determine whether the initiation of apoptosis would be 
specific to cells expressing HIV-1 protease.  
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5.5 Apoptosis induction in “HIV-infected” cells treated with NTA-gold nanoparticles 
functionalised with CD4-targeting peptide and mutant caspase-3 
Since the CD4-targeting peptide-Mutant caspase-3 gold nanoparticles are expected to induce 
apoptosis in the “HIV-infected” cells, the cells were treated with the nanoparticles and 
apoptosis was assessed by the APOPercentage™ assay, as described in section 2.17.3. Cells 
were grown to near visual confluency and treated with CD4-targeting peptide-Mutant 
caspase-3 gold nanoparticles. From the APOPercentage™ data, represented by Figure 5.9, the 
negative control (untreated cells), showed that about 3 % of the cells were positive for 
apoptosis. The positive control (cells treated with 50 % ethanol), showed that more than 98 % 
of the cells were positive for apoptosis. Cells expressing both CD4 and HIV-1 protease 
demonstrated a less than significant percentage of apoptotic cells in cells treated with NTA-
nanoparticles only and cells treated with NTA-CD4-targeting peptide nanoparticles. In cells 
treated with NTA-nanoparticles functionalised with mutant caspase-3, only 12 % of cells had 
undergone apoptosis. When treated with NTA-CD4-targeting peptide-mutant caspase-3 
nanoparticles, only 15 % of cells had undergone apoptosis. Since this assay requires greater 
than 15 % for cells to be considered significantly apoptotic, these results do not conclude that 
the cells undergo increased levels of apoptosis.  
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Figure 5.9. Measurement of apoptosis in “HIV-infected” cells treated with NTA-functionalised gold 
nanoparticles functionalised with CD4-targeting peptide and mutant caspase-3.  
 
5.6 Morphological analysis of “HIV-infected” cells treated with NTA-CD4-targeting 
peptide-mutant caspase-3 gold nanoparticles 
To determine whether any morphological changes occurred in cells after 6 hours of treatment, 
light microscope images were taken at 20 X magnification using a Leica EC3 digital camera. 
Figure 5.10 demonstrates the morphological changes that took place in transfected cells 
treated with various NTA-nanoparticles after 6 hours.  
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Figure 5.10. Light microscope images of CHO cells transfected with NTA-CD4-targeting 
peptide-mutant caspase-3 nanoparticles. A) Untreated transfected cells. B) Transfected cells treated 
with 50 % ethanol (positive control). C) Transfected cells treated with NTA-nanoparticles only. D) 
Transfected cells treated with NTA-CD4 targeting peptide nanoparticles. E) Transfected cells treated 
with NTA-mutant caspase-3 nanoparticles. F) Transfected cells treated with NTA-CD4-targeting 
peptide-mutant caspase-3 nanoparticles. Images were captured at 20 x magnification. 
  
After 6 hours of treatment, untreated cells, Figure 5.10 A) remained unchanged, the positive 
control B) (cells treated with ethanol) changed morphology by rounding up and lifting from 
the well. Cells treated with NTA-nanoparticles, indicated by Figure 5.10 C) did not 
demonstrate any distinct morphological changes. Cells treated with NTA-CD4-targeting 
peptide nanoparticles (D) were also relatively unaffected, although the cells appeared more 
sindle shaped the cells did not detach from the plate. Cells treated with NTA-mutant caspase-
3, however, showed cells starting to round up and the formation of a number of vesicles 
within cells, as seen in Figure 5.10 E). Cells treated with NTA-CD4-targeting peptide-mutant 
caspase-3 nanoparticles demonstrated an even greater incidence of vesicle formation after 6 
hours of treatment, as indicated by Figure 5.10 F). Both NTA-mutant caspase-3 and NTA-
CD4-targeting peptide-mutant caspase-3 particles caused cell detachment. 
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 5.7 Summary  
To determine which gold nanoparticles would cause the least amount of toxicity in cells 
before being conjugated to our death-inducing protein, nanoparticles with various 
functionalities were tested on cells. The NTA-functionalised gold nanoparticles demonstrated 
the lowest levels of apoptosis, and were therefore selected as the base particles for the 
conjugation of our CD4-targeting peptide as well as our death-inducing mutant caspase-3. 
The NTA group also made it possible to functionalise our proteins to the nanoparticle by 
means of nickel titration. The optimal concentration of nickel was determined to be 0.5 mM 
and was used to conjugate CD4-targeting peptide as well as mutant caspase-3 to form NTA-
CD4-targeting peptide-mutant caspase-3 gold nanoparticles. These particles were used to 
treat cells expressing CD4 and HIV-1 protease, thereby representing HIV-infection, and 
apoptosis was measured. The APOPercentage™ assay revealed insignificant levels of 
apoptosis in cells transfected with CD4 and HIV-1 protease, when treated with NTA-CD4-
targeting peptide-mutant caspase-3 nanoparticles. Morphological data, however, revealed that 
after 6 hours of treatment with NTA-CD4-targeting peptide-mutant caspase-3 nanoparticles, 
cells no longer resembled their untreated counterparts and increased levels of vacuole 
formation within cells was seen. From the morphological data, it is clear that after 6 hours of 
treatment, cells are being affected by the NTA-CD4-targeting peptide-mutant caspase-3 
nanoparticles. An extension of this 6 hour experiment would most likely reveal a great deal 
more as to whether apoptosis is the mechanism of cell death occurring here.  
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CHAPTER 6. DISCUSSION AND CONCLUSION 
6.1 Introduction 
Vocero-Akbani and colleagues previously demonstrated that a mutant form of caspase-3 that 
was only cleavable by HIV-1 protease can be used to induce apoptosis in HIV infected cells 
(Vocero-Akbani et al., 1999). The study by Vocero-Akbani made use of protein transduction 
to deliver the mutant form of caspase-3 to the HIV infected cells. Consequently, the strategy 
employed by Vocero-Akbani lacks specifity. The aim of this project was to use the same 
strategy, but to specifically target the delivery of the mutant caspase-3 to HIV infected cells 
using gold nanoparticles. These nanoparticles can potentially be used to treat HIV infection, 
since the induction of apoptosis in HIV infected cells can reduce viral load in HIV patients. 
To achieve this, a model cell line that resemble an HIV infected cell was generated using 
CHO cells. The CHO cells were mutagenised so that these cells express both CD4 (on the 
cell surface) as well as HIV-1 protease (in the cytosol). Gold nanoparticles conjugated with a 
CD4 targeting peptide and mutant caspase-3 were synthesised. The targeting peptide will 
specifically deliver the nanoparticles to bind to CD4 expressing cells and the mutant caspase-
3 will activate apoptosis in cells containing HIV-1 protease. Upon cleavage of the mutant 
caspase-3 by HIV-1 protease, caspase-3 becomes active, thereby resulting in the initiation of 
apoptosis or programmed cell death in of HIV-infected cells.  
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6.2 Cloning and stable expression of pEGFP-N3-CD4 and HIV-1 protease-pcDNA™ 
3.1D/V5-His-TOPO in CHO cells 
In order to generate a cell line expressing both CD4 and HIV-1 protease, CD4 was first PCR 
amplified and run on an agarose gel. The size of the PCR product corresponded to ~ 1.2 kb, 
the expected size for the CD4 gene. The PCR product, as well as the expression vector, 
pEGFP-N3, were digested with the appropriate restriction enzymes before cloning the PCR 
product into the vector.  
Colony PCR was done to identify clones into which the cloned PCR product was cloned. 
Three of the positive clones, clone 3, 4 and 5 were randomly selected to confirm that CD4 
was indeed cloned into pEGFP-N3. Translation of the nucleic sequence data by in silico 
translation using the ExPASy tool revealed a 99 % amino acid similarity between human 
CD4 and the PCR product that was cloned into pEGP-N3. The single mismatched amino acid 
in the compared sequences was determined to be negligible since it does not affect the 
function of the protein, as determined by the ExPASy protein function analysis tool. 
In a similar way, HIV-1 protease was PCR amplified, digested and cloned into pcDNA™ 
3.1D/V5-His-TOPO. Colony PCR was done to to identify clones into which the cloned PCR 
product was cloned. In Figure 3.7, a faint band, of diminished intensity when compared to the 
other bands on the gel, can be seen in lane 12, the negative control. The presence of this band 
suggests that there may have been overflow from the PCR product in lane 11, resulting in a 
faint, similarly-sized band where no DNA should have been present. Due to the intensity of 
the other bands on the gel, the faint band was considered to be negligible. Five of the clones 
were randomly selected and sent for sequencing. Analysis of the sequence data revealed a 
100 % match between HIV-1 protease and the PCR product cloned into pcDNA™ 3.1D/V5-
His-TOPO.  
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6.3 Transfection and evaluation of expression of CD4-pEGFP-N3 and HIV-1 protease-
pcDNA™ 3.1D/V5-His-TOPO in CHO cells 
Both pEGFP-N3 and pcDNA™ 3.1D/V5-His-TOPO use neomycin resistance as a selectable 
marker to select for transfected cells. Consequently pcDNA™ 3.1D/V5-His-TOPO-HIV-1 
protease was transfected at ten times the concentration of pEGFP-N3-CD4. After 7 days of 
selection with G-418 none of the control cells (untransfected cells) were viable. Cells  co-
transfected with pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease and pEGFP-N3-CD4, 
however, were still viable and proliferating in the presence of G-418 after 7 days.  
The transfection of cells with pEGFP-N3-CD4 will result in the expression of CD4 as a 
fusion protein with GFP. Since GFP is a fluorescent protein, fluorescence microscopy was 
used to confirm the expression of CD4-GFP. The results demonstrated that approximately 70 
% of transfected cells were positive for CD4-GFP expression. This indicated that only 70 % 
of the cell population had been successfully transfected with the pEGFP-N3-CD4 construct. 
To generate a homogenous population of these transfected cells, live cell sorting was 
performed using a Fluorescent Activated Cell Sorter. Once sorted, more than 99 % of the cell 
population was detected in the FL1 channel of the cytometer, indicating the expression of 
GFP. This therefore confirmed that the sorted cell population was a relatively pure population 
of CD4-pEGFP-N3 expressing cells. 
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Since the concentration of pcDNA™ 3.1D/V5-His-TOPO-HIV-1 protease plasmid was ten 
times higher than the concentration of pEGFP-N3-CD4, it can be assumed that pcDNA™ 
3.1D/V5-His-TOPO-HIV-1 protease was also successfully transfected. A model cell line , 
CHO-HIV-1 protease-CD4, expressing both HIV-1 protease as well as CD4 was therefore 
successfully generated, and can be used to test nanoparticles as pro-apoptotic agents.  
 
6.4 Recombinant expression and purification of mutant caspase-3 for conjugation to 
NTA-functionalised gold nanoparticles 
In the study by Vocero-Akbani and colleagues in 1999, they were able to demonstrate the 
activation of apoptosis of HIV-infected cells by using site-directed mutagenesis to generate a 
mutant form of caspase-3. This mutant caspase-3 contained the activation sites for HIV-1 
protease that allowed the cleavage of the caspase by the HIV-1 protease, resulting in 
apoptotic cell death of HIV-infected cells.  
Based on the aforementioned study, we attempted to design mutant caspase-3 that could be 
activated in the presence of HIV-1 protease expressed in mammalian cells representing HIV-
infection, as described in Chapter 3.  
In order to achieve this, an NTA-functionalised gold nanoparticle bi-conjugated to a His-
tagged CD4-targeting peptide and a His-tagged mutant caspase-3 protein was generated. A 
DNA sequence for the recombinant expression of mutant caspase-3 in pET21b expression 
vector was designed based on the study by Vocero-Akbani and colleagues. The sequence was 
submitted to GenScript for synthesis. BL21 codon plus™ E.coli cells were transformed with 
this construct. An expression screen revealed the expression of a ~33 kDa protein, which is 
the expected size for the mutant caspase-3.   
 
 
 
 
127 
 
As noted in section 4.3, the construct was expressed equally well in both the uninduced and 
induced samples. This is most likely attributed to leaky expression, a phenomenon caused by 
the presence of small amounts of lactose present in culture media during the bacterial 
expression of proteins (Studier, F. W., 2005). 
After screening for the mutant form of caspase-3, the process was scaled up for the 
expression and purification of the protein. To confirm that the eluted protein sample was 
indeed mutant caspase-3, a Western blot using a caspase-3 antibody was done. The signal 
from the Western blot confirmed that the eluted protein was a caspase-3 related protein, and 
most likely mutant caspase-3.  
NTA-functionalised gold nanoparticles were used as base particles for the generation of a 
gold nanoparticle containing both a CD4-targeting peptide, as well as a mutant caspase-3. 
This particle, Au-NTA-CD4-Mutcasp3, was assembled by adding His-tagged CD4 targeting 
peptide and His-tagged mutant caspase-3 to NTA-functionalised gold nanoparticles and 
incubating at room temperature overnight. To ascertain that the particle was indeed 
functionalised, TEM and EDX were performed to respectively determine the size and 
composition of nanoparticles. 
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6.5 Detection of cytotoxicity and apoptosis using the ApoTox-Glo™ Triplex Assay on 
CHO-HIV-1 protease-CD4 cells treated with Au-NTA-CD4-MutCasp3 
Due to their inert nature, as well as the ability to attach various biomolecules to them, gold 
nanoparticles were used as vehicles for the targeted delivery of a death-inducing protein, 
mutant caspase-3. Nanoparticles were targeted to cells expressing CD4 and HIV-1 protease 
by conjugating the particles to a CD4-targeting peptide. In order to facilitate conjugation, and 
based on the low levels of cytotoxicity produced in cells, NTA-functionalised nanoparticles 
were selected.  
 
6.5.1 Cytotoxicity in CHO-HIV-1 protease-CD4 cells 24 hours after treatment with Au-NTA-
CD4-MutCasp3 
Cytotoxicity of CHO-HIV-1 protease-CD4 cells treated for 24 hours with Au-NTA-CD4-
MutCasp3 was determined using the ApoTox-Glo™ Triplex Assay cytotoxicity reagent. 
From this data, as described in Figure 5.8 of Chapter 5, it can be deduced that as the 
nanoparticle concentration increases, the level of cytotoxicity decreases. Based on this data, 
the LC50 of the functionalised nanoparticles was determined to be approximately 500 pM, the 
concentration at which half the cell population was no longer viable. This concentration of 
NTA-gold nanoparticles was used to perform a 50:50 ratio of His-tagged CD4 targeting 
peptide to His-tagged mutant caspase-3 functionalisation of NTA-gold nanoparticles.  
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6.5.2 Apoptosis in CHO-HIV-1 protease-CD4 cells 6 hours after treatment with  
Au-NTA-CD4-MutCasp3 
Apoptosis was measured by the APOPercentage
TM
 assay in CHO-HIV-1 protease-CD4 cells 
6 hours after treatment with Au-NTA-CD4-MutCasp3. The APOPercentage
TM
 data, indicated 
in Figure 5.9, suggests that after 6 hours of treatment with Au-NTA-CD4-MutCasp3, only 15 
% of cells underwent apoptosis. In order for the assay to show significant levels of apoptosis, 
15 % or greater levels of apoptosis must be seen. This could therefore not be considered a 
significant resultThe experiment was, however, limited since the duration of treatment was 
only 6 hours. In order to more accurately determine the mechanism of cell death, as well as 
whether there is a marked increase in apoptosis, apoptosis would need to be measured at 
additional time points.  
The percentage of apoptosis in cells treated only with NTA-mutant caspase-3 nanoparticles 
was ~ 12 %, which is not much lower than cells treated with the fully functionalised 
nanoparticle. Even though the number of cells that undergo apoptosis when treated with 
NTA-mutant caspase-3 nanoparticles and Au-NTA-CD4-MutCasp3 is ~ 12 % and 16 % 
respectively, this gap could widen with an increase in treatment duration to demonstrate that 
the death-inducing nanoparticles are, indeed, targeted to CHO-HIV-1 protease-CD4 cells 
expressing CD4 and HIV-1 protease. When one compares the apoptosis data for transfected 
cells treated with Au-NTA-CD4-MutCasp3 to that of untransfected cells treated with the 
same, it was also determined that a low level of apoptosis, ~ 7 %, is detected. This was an 
unexpected result, but could very possibly be attributed to the occurrence of auto-cleavage of 
the mutant caspase-3.  
Auto-cleavage is a common occurrence where proteins are cleaved in the absence of an 
activation enzyme. The phenomenon usually occurs as a result of changes in pH and 
 
 
 
 
130 
 
temperature. In order to minimise the occurrence of auto-cleavage in future, various salt 
concentrations and temperatures could be tested to determine which conditions would be 
optimal.  
 
6.5.3 Morphological analysis of CHO-HIV-1 protease-CD4 cells 6 hours after treatment with 
Au-NTA-CD4-MutCasp3  
Before apoptosis was measured in cells, as described section 6.4.2, light microscopy was 
performed to identify morphological changes that had taken place 6 hours after treatment, as 
displayed in Figure 5.10. When visualised under a light microscope, the negative control, 
containing untreated cells only, displayed the usual morphology of CHO cells. The positive 
control, containing a known inducer of apoptosis, displayed rounding up and lifting of cells 
from the culture surface, indicating cell death. CHO-HIV-1 protease-CD4 cells treated with 
NTA-nanoparticles only did not display any noticeable morphological changes, as was the 
case with cells treated with NTA-CD4 nanoparticles.  
Cells that were treated with Au-NTA-CD4-MutCasp3 nanoparticles did, however, 
demonstrate distinctive morphological changes. After 6 hours of treatment, these cells 
demonstrated high levels of vacuole formation, seen in nearly the entire cell population. The 
same phenomenon occurred in cells treated with NTA-CD4-targeting peptide-mutant 
caspase-3. This marked increase in vacuole formation is reminiscent of a process termed 
autophagy, a catabolic process during which a membrane develops around cell contents, 
forming vacuoles. These vacuoles are then transported to lysosomes, where they undergo 
degradation.  
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Although apoptosis has been classified as the primary form of programmed cell death, recent 
years have seen the advent of autophagic death as a secondary type of cell death, based 
largely on morphological changes (Debnath et al., 2005).  
Based on the morphological data alone, as displayed in Figure 5.10, it would appear that after 
6 hours of treatment, these cells do undergo autophagy. Although autophagy is considered to 
be a mechanism that protects cells from proteotoxic and oxidative stress, it has also been 
linked to apoptosis itself. Cells have been known to alternate between apoptosis and 
autophagy, suggesting that autophagy may be a supporting mechanism of cell death and that 
both processes could very well share the same pathways in response to cellular stress (Maiuri 
et al., 2007).  
 
6.6 Conclusion 
The results of this study show that NTA-gold nanoparticles functionalised with a CD4-
targeting peptide as well as a death-inducing mutant caspase-3 results in cell death after 6 
hours of treatment. The APOPercentage™ data suggests that these cells start to undergo 
apoptosis after 6 hours. Additionally, the morphological data demonstrates the formation of a 
large number of vacuoles by these cells, suggesting the occurrence of autophagy. This 
preliminary data suggests that gold nanoparticles could potentially serve as effective drug 
delivery tools and that the mutant caspase-3, coupled to these particles, results in death in 
cells representing HIV-infection, irrespective of the mechanism of death. Future investigation 
will focus on the improvement of specificity of mutant caspase-3 for cells expressing HIV-1 
protease by limiting the occurrence of auto-cleavage. Longer duration of treatment could also 
shed light on the extent of cell death that takes place in “HIV-infected” cells.  
 
 
 
 
132 
 
Cellular uptake studies will also be done to determine the concentration of particles within 
cells, as well as whether uptake is greater in those cells expressing CD4. Once the therapeutic 
agent has proven to be successful in vitro, an animal model of HIV will be treated with 
functionalised gold nanoparticles to determine whether they induce apoptosis in an in vivo 
setting, and thereby reduce viral load towards the eradication of HIV-infected cells. 
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